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 The burden of liver disease in Egypt is exceptionally high, maintaining the 
highest prevalence of hepatitis C virus (HCV) worldwide, as well as rising rates of 
hepatocellular carcinoma (HCC).  The foundation of the HCV epidemic in Egypt is 
generally attributed to a mass public health campaign to eliminate schistosomiasis during 
the 1960’s-1980’s.  Questions remain regarding the precise incidence of HCV during this 
campaign, the future burden of chronic disease those affected will experience, and the 
future direction of HCV and liver disease now that this campaign has ended.  This 
dissertation offers a series of studies designed to precisely define the nature of HCV 
infections and HCC in Egypt, spatially and temporally, as well as predict the future 
burden and impact on the Egyptian population.  Specific methods included analyses of  
HCC case data collected from the Gharbiah Population-based Cancer Registry (GPCR) to 
define demographic and spatial trends in the occurrence of HCC in Egypt, in addition to a 
meta-analysis and the construction of two mathematical models designed to calculate 
historic incidence of HCV and project future HCV-related health complications.  Results 
identified significant heterogeneity in HCC occurrence with respect to sex and district of 
residence.  More in-depth investigation identified significant spatial clustering of HCC 
associated with clusters of squamous cell carcinoma of the bladder (a proxy measure for 
schistosomiasis burden).  Meta-analysis revealed the HCV epidemic is marked by a 
three-way interaction between time, geographic region, and whether individuals reside in 
 x
urban or rural environments.  Modeling techniques confirmed the presence of a cohort 
effect among those affected by the public health campaign, identified by a spike in 
incidence among those presently aged 30-50 years.  The natural history model predicted 
Egypt will experience significant morbidity and mortality over the next 20 years due to 
the HCV epidemic.  Our findings highlight the significance of developing an integrated 
strategy for the prevention of HCV infection.  Unquestionably, additional factors 
contributing to liver disease burden remain to be elucidated.  This information is crucial 
and should help define the complex etiology of liver disease in Egypt, enabling policy 
makers to create targeted, more efficient prevention and control programs. 
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BACKGROUND AND PUBLIC HEALTH SIGNIFICANCE 
 
Impact of liver cancer.  Worldwide, primary liver cancer (PLC) ranks fifth 
among cancer incidence, with an estimated 0.5 – 1 million cases diagnosed each year, 
and third among cancer mortality.  It accounts for 5.6% of all human cancers, with 7.5% 
among men and 3.5% among women.  Developing countries generally have a greater 
share of the burden, however, where it can rank as the leading cause of cancer incidence 
and mortality among males.1-5  Hepatocellular carcinoma (HCC) and cholangiocarcinoma 
are the two major types, accounting for 85% and 10% of all primary liver cancers 
respectively.2-4  The following report will focus exclusively on HCC, as it is by far the 
dominant malignancy and has the greatest relevance to public health.  
Cholangiocarcinoma is generally associated with specific occupational exposures and 
smaller risk groups, whereas the general population is susceptible to HCC, requiring 
public health programs of a much larger scale.4   
Approximately 81% of all HCC cases are found in Asia and Africa, with China 
producing 53% of these cases.6  In these high-risk regions, rates begin increasing after 
age 20 and typically peak or stabilize at age 50 and older.2,4,5  Not only does this lead 
directly to a drain on health resources, it also contributes to an indirect loss of the 
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country’s productivity.  Considering the age group affected and the high rate of mortality, 
this disease removes people who are the most economically productive and who hold a 
great deal of social responsibility in terms of caring for children and the elderly.  Despite 
public health’s longstanding knowledge of the problem, few strides have been made 
when compared to other cancers such as breast and prostate cancer.  This can be 
attributed to the complex combination of liver anatomy and the insidious nature of liver 
cancer’s primary risk factors (i.e. hepatitis B virus, hepatitis C virus, aflatoxin exposure, 
and excessive alcohol intake).1-5 
Liver anatomy and function.  The liver, along with its companion biliary tree 
and gall bladder, is located in the upper-right quadrant of the abdomen (Figure 1.1).  
Existing at the crossroads between the digestive tract and the other functions of the body, 
the liver is charged with the enormous task of maintaining metabolic homeostasis.  This 
involves processing normal dietary elements, such as lipids and carbohydrates, as well as 
detoxifying and excreting waste products and pollutants.8-9  Consequently, hepatic 
malfunction can have dramatic repercussions.  
The liver holds about one pint (13 percent) of the body's blood supply at any 
given moment.  The liver consists of two main lobes, both of which are made up of 
thousands of lobules.  These lobules are connected to small ducts that connect with larger 
ducts to ultimately form the hepatic duct.  The hepatic duct transports the bile produced 
by the liver cells to the gallbladder and duodenum (the first part of the small intestine). 8-9  
Incoming blood arrives via the portal vein (60%-70% of blood flow) and the hepatic 
artery (30%-40% of blood flow) through the porta hepatis.  The common hepatic bile 
duct exits in this same region.  The initial branches of artery, vein, and bile duct lie just 
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outside the liver, but the remaining branches run roughly in parallel within the liver to 
form the portal tracts.  The terminal vessels of the portal vein and hepatic artery supply 
blood to the expanse of hepatic parenchyma.  Blood is ultimately collected and exits into 
the inferior vena cava, lying posterior to the liver. 8-9 
The liver performs several vital functions: it processes and stores many of the 
nutrients absorbed from the intestine, it secretes bile into the intestine to help absorb 
nutrients, and it also makes some of the clotting factors needed to stop bleeding from a 
cut or injury.  In addition, the liver plays a very important part in removing toxic wastes 
from the body, of which alcohol and dietary toxins are particularly noteworthy.  The 
enormous functional reserve of the liver often masks the clinical impact of early liver 
damage. 8-9  With progression of diffuse disease or disruption of bile flow, however, the 
consequences of liver damage can easily become life-threatening. 
The most severe consequence of liver disease is hepatic failure, which will only 
occur once 80%-90% of hepatic functional capacity is removed.9  By far the most 
common route to hepatic failure is the endpoint of chronic hepatitis or alcoholic liver 
disease ending in cirrhosis.  Approximately 85% of patients infected chronically with 
hepatitis B virus (HBV) will develop cirrhosis, and nearly 95% of patients with chronic 
hepatitis C virus will develop cirrhosis.3,10  Cirrhosis can be defined by three main 
characteristics: parenchymal nodules, disruption of the architecture of the entire organ, 
and fibrous septa that replace multiple adjacent lobules.  In particular, the parenchymal 
fibrosis is typically diffuse, extending throughout the liver.  Once the fibrosis has 
developed, it is generally irreversible.  Although alone cirrhosis is among the leading 
causes of death in the world, it also serves as an important precursor to HCC.4   
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HEPATOCELLULAR CARCINOMA: RISK FACTORS 
Hepatitis B Virus.  To date, the dominant risk factor for HCC has been HBV, 
accounting for nearly 75%-80% of all cases worldwide.  There are approximately 350 
million hepatitis B carriers worldwide, of which one quarter are expected to develop 
serious liver disease, including cirrhosis and HCC.  In addition, HBV infection directly 
accounts for nearly 1 million deaths, and indirectly it accounts for 60 million deaths from 
chronic liver disease annually.11-13  The problem disproportionately affects developing 
countries where transmission occurs at an early age, increasing the likelihood of chronic 
hepatitis and subsequent HCC (Figure 1.2).14  
Hepatitis B virus (HBV) is a DNA virus of from the Hepadnaviridae family.  It is 
transmitted via blood products and other bodily fluids.  It is unique in that all regions of 
the viral genome encode protein sequences.11,13-14  The association between HBV and 
HCC was suggested by the high incidences of HCC in regions where HBV infection is 
hyper-endemic.  The risk of eventually developing HCC is inversely related to the age of 
acquisition of HBV.  Thus, children exposed to HBV have a much greater chance of 
becoming chronic HBV carriers than do newly infected adults.14   
In 1994, a working group of the International Agency of Research on Cancer 
(IARC) officially concluded that HBV is a carcinogen in humans.  The incorporation of 
HBV DNA into tumor DNA has been well documented.   Molecular studies have shown 
that HBV DNA is present in the tumor tissues of HCC patients who are chronic carriers 
of HBV, and that 10% to 29% of patients with HCC harbor markers of past HBV 
infection.15-17  Of particular significance is the protein from the X region (HBX).  It is 
necessary for virus replication and acts as a transcriptional transactivator of the viral 
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genes and a wide variety of host gene promoters.  This protein is thought to play a key 
role in the causation of HCC.18-22   
Hepatitis C Virus.  The hepatitis C virus (HCV) is an enveloped single-stranded 
RNA virus from the Flaviviridae family.  The virus is inherently unstable, leading to 
multiple types and subtypes, which has seriously limited efforts to develop an effective 
vaccine.23-26  Of particular significance is the fact that elevated titers of anti-HCV IgG 
occurring after an active infection do not confer immunity.  Thus, it is characteristic for 
patients to experience repeated bouts of hepatic damage, resulting from reactivation of 
preexisting infection or emergence of an endogenous, newly mutated strain.  Cirrhosis 
typically develops within 5-10 years of infection.26-29 
Hepatitis C virus (HCV) has been suggested as a major cause of HCC in areas 
where the incidence of HBV infection is declining or already low.  The prevalence of 
anti-HCV antibodies among patients with HCC ranges from around 30% in China and 
South Africa to 70% to 80% in southern Europe, Egypt, and Japan.  Chronic HCV 
infection coexists with HBV infection or alcohol abuse in 20% of cases.23-24  In areas 
where HBV is hyper-endemic, such as Taiwan, the prevalence of anti–HCV antibodies is 
much higher among hepatitis HBsAg–negative HCC patients than among HBsAg–
positive HCC patients.  Sheu, et al. found a higher incidence of HCV RNA in serum and 
liver tissue of HBsAg–negative patients with HCC than in samples from HBsAg–positive 
patients, suggesting that HCV infection is important in the pathogenesis of HCC in 
HBsAg–negative patients.30  Prospective studies have indicated that more adults are long-
term carriers of HCV than of HBV.31-39  In a group of patients with transfusion-associated 
liver disease, the interval between blood transfusion and diagnosis of anti–HCV 
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antibody–positive HCC was as long as 29 years.26  The IARC working group determined 
that chronic infection with HCV is carcinogenic in humans.  It has been hypothesized that 
HCV is probably the major viral cause of HCC in areas with a low incidence of HBV 
carriers.  Although there is no evidence that the virus itself is oncogenic, it has been 
suggested that this agent may promote carcinogenesis through the induction of chronic 
necro-inflammatory hepatic activity and liver cirrhosis.28, 30-34,37,39  Approximately 90%-
95% of patients with HCV-associated HCC also have cirrhosis.33-34,40 
Aflatoxin Exposure.  Aflatoxins are mycotoxins produced by the fungi 
Aspergillus flavus and A. parasiticus.  These toxins may contaminate food stored in 
humid conditions.  Animal studies suggest that aflatoxin B1 (AFB1 ) is a carcinogen.1-
5,8,41-43  Early case-control studies, however, failed to find a significant association 
between human HCC and aflatoxin exposure.  In Mozambique, South Africa, Swaziland, 
China, and Taiwan, the use of biomarkers has shown a statistically significant correlation 
between dietary aflatoxin exposure and HCC mortality or morbidity.43  Areas with high 
aflatoxin contamination overlap areas with high rates of HBV infection. Some 
investigators propose that the combination of aflatoxin and HBV infection has a 
synergistic effect that leads to oncogenesis.  In liver cells, aflatoxin is metabolized by the 
microsomal mixed-function oxidase.  Aflatoxin B1-2-3-epoxide, a highly reactive 
metabolite of aflatoxin B1 , is capable of binding to DNA and RNA and is thought to be 
the main carcinogenic metabolite of aflatoxin.8,41  Aflatoxin B1 is known to induce a 
mutation at codon 249 of p53.41,43  This mutation could be one of the mechanisms leading 
to HCC. 
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Excessive Alcohol Intake.  Cirrhosis is the most important risk factor for HCC 
and underlies HCC in more than 80% of the cases.  The annual incidence of HCC among 
patients with cirrhosis ranges from 3% to 5%.1-5,8-9   Autopsy studies of patients with 
cirrhosis have shown a prevalence of HCC ranging from 20% to 80%.  In Africa and Asia 
the cause of underlying liver cirrhosis may be related to exposure to HBV or HCV.  In 
developed nations, however, cirrhosis is most commonly linked to alcohol abuse.1-3,40  
Although research providing direct causal inference is not overwhelming, several 
laboratory and epidemiologic studies conclude that alcohol plays an indirect role in 
hepatocarcinogenesis.1-5  The reported risk of developing HCC among individuals with 
alcoholic cirrhosis ranges from 3% to 15%.  The risk may actually increase after cessation 
of alcohol consumption, but this increase results from an extended lifespan rather than 
from a direct effect on tumor formation.5,8  Hepatocellular carcinoma has been observed 
in 60% to 80% of patients with macronodular cirrhosis and in 3% to 10% of the patients 
with the micronodular pattern.4-5  
 
EGYPT AND LIVER DISEASE 
Egypt holds a unique position in the epidemiology of hepatitis and liver cancer.  It 
has successfully implemented the hepatitis B virus (HBV) vaccine and now boasts 95%-
100% coverage.44-46  Despite this major public health achievement, liver cancer continues 
to be the second highest cause of cancer incidence and mortality in men.  The age 
standardized rate is approximately 20.6 in males and 5.2 in females.  For males, this rate 
is 7 times the second-highest rate found in the Middle East Cancer Consortium (Israeli 
Jews) and more than 3 times the rate reported by US SEER.47  Egypt is also home to the 
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highest prevalence of hepatitis C virus (HCV) in the world (Figure 1.3), with an overall 
rate of approximately 22%.48-60  In populations of blood transfusion recipients over the 
age of 30, this rate has been reported to be as high as 73%, and in the general population 
aged 40-60 years this rate can be as high as 55%.  At the same time, the rate in children is 
much lower, ranging between 2-10%.  While the rate in children is much lower than that 
in the older population, it is still considered high by World Health Organization (WHO) 
standards, where rates greater than about 4% are considered high.51,53,59  Therefore, as 
more and more countries adopt the HBV vaccine, HCV could become the dominant force 
driving liver cancer rates worldwide.49-51,61  Understanding the HCV epidemic in Egypt 
will aid in the global effort to fight HCV and liver cancer as well as provide insights into 
viral etiology and pathogenesis that may help in future situations with newly emerging 
infectious agents. 
Most scholars will agree that the HCV story in Egypt must be divided into two 
chapters: pre 1980's infection and post 1980's infection.  In the population aged older than 
20-30 years, the vast majority of infection can be explained by the intravenous treatment 
for schistosomiasis (PAT) and other iatrogenic exposures such as blood transfusion.62-69  
The tragic irony of the situation in Egypt is that a mass public health campaign designed 
to dramatically reduce the burden of schistosomiasis led to a new public health crisis: the 
HCV epidemic.  This campaign extended from the 1940's through the 1970's, with 
probably the peak transmission occurring during the 1960's and 1970's.  In 1982, 
praziquantal, an oral treatment for schistosomiasis, was introduced, and use of PAT 
rapidly declined.  In addition, throughout the 1980's numerous measures were adopted to 
limit iatrogenic exposures, and they appear largely to have been effective.63,66 
 9
The question that remains for Egypt, therefore, is what will the shape of the 
epidemic curve be now that PAT and hospital-based infections no longer contribute to the 
picture of transmission.  Indeed the rates among children are significantly lower, but it 
nevertheless appears that HCV is capable of sustaining transmission.  The problem is that 
presently we have little explanation for this transmission.   
The studies that have tried to examine this tend to divide the study population into 
groups older than 20 years and younger than 20 years.  This has to do with the inherent 
confounding between age and exposure (namely PAT).  Types of exposures examined 
have included formal medical procedures, informal medical procedures, hookah use, etc.  
In general, there tends to be limited association between anti-HCV positivity and 
receiving medical procedures from an informal practitioner, such as circumcision.  In all 
studies reviewed, however, R-squared values were rarely greater than 0.1, which means 
that 90% of the infections seen in the younger population cannot be effectively explained 
by the exposures measured.51,53-59  This is compounded by the fact that the Egyptian 
population does not appear to have the risk factors seen in other regions of the world with 
higher HCV prevalence, for example IVDU or HIV/HCV coinfection.   
It seems clear, therefore, that researchers need to broaden their scope of potential 
risk factors for transmission.  It has been observed anecdotally that family members in 
prolonged close contact could have greater risk of infection, but this has yet to be directly 
studied.70-73  It is possible that exposure to the virus may require intense close contact and 
the exposures could be cumulative.  To properly study this point, a prospective family 
cohort study would be desired to follow family members of anti-HCV positive and 
negative individuals and follow-up for new infections.  Suggesting this design would 
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likely be premature at this point.  An appropriate step would be to provide the 
intermediate link between anecdotal observation and cause-and-effect demonstration.   
Another glaring gap in the understanding of the HCV epidemic in Egypt is the 
complete lack of information regarding incidence rates.  Due to the nature of the 
infection, longitudinal incidence studies would be very difficult to carry out.  Initial 
infection is rarely symptomatic, and chronic carriage is insidious.  Nevertheless, it is 
difficult to predict the burden HCV will have on the community in the future and what 
priority it should have in health policy if the rates of transmission are unknown.  Up to 
this point, incidence rates have been inferred from prevalence.48-52,59-60,70  The prevalence 
among children is much lower than it is among adults who were infected during the PAT 
campaign, and therefore incidence rates must be lower now.  Though it appears clear that 
transmission rates have declined since the early 1980's, it is still essential to 
quantitatively characterize the nature of the HCV problem in order to make informed 
predictions about the future of the epidemic and define appropriate health policy to 
address the crisis. 
Because HCV is such an important predictor of hepatocellular carcinoma (HCC), 
it frequently receives special attention from the public health community in Egypt.  This 
should not be at the exclusion of all other risk factors, however.  There are many 
recognized risk factors for HCC, including but not limited to HBV, HCV, aflatoxin 
exposure, alcohol consumption, and tobacco use.  In addition, a number of other 
environmental agents could act as promoters in concert with the above risk factors 
(pesticides, heavy metals, etc).74-76  It is necessary to identify the Egypt’s HCC profile in 
terms of risk factor distribution.  Identifying clusters of cases associated with certain risk 
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factors can also help policy makers locate risk groups and design targeted interventions 
that will improve efficiency while at the same time protecting the largest number of 
susceptible individuals in the population. 
Fortunately, Egypt provides an excellent location for performing studies to 
understand the epidemiology of liver cancer.  It has successfully created a population-
based cancer registry that has been functional since 1999.  In addition, the Egyptian 
National Liver Institute is a unit dedicated to understanding liver disease throughout the 
country.  Such a well established infrastructure is a rich resource that should be 
recognized by the research community.  This administrative organization is in addition to 
the unique exposure status of the population, with the highest levels of HCV in the world, 
dramatically declining levels of HBV, and large exposures to environmental 
contaminants, owing to its status as a country in the midst of an industrial transition.  
Therefore, not only can Egypt serve as host to studies concerning the natural history of 
HCV, but it should be the focus of subsequent liver cancer studies as well. 
Prior cancer studies in Egypt have focused on utilizing qualitative instruments to 
assess the likelihood that specific exposures led to carcinogenesis.77-82  They start with 
liver cancer cases and attempt to document infection with HBV and HCV as well as any 
exposures to environmental agents.  These studies have shown the increasing importance 
of HCV in liver cancer, estimated to account for 40-50% of liver cancer cases, and the 
declining influence of HBV and HBV/HCV infection (25% and 15% respectively).79-80,82  
These studies have also documented an overall increase in the prevalence of liver cancer 
in Egypt, from approximately 4.0% in 1993 to 7.3% in 2003.79  This increase in liver 
cancer is generally attributed to HCV.  Since chronic HCV does not typically lead to 
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carcinogenesis for 10-30 years following infection, the rates of liver cancer can be 
expected to continue increasing until the cohort of PAT-related infected individuals has 
worked its way through.49,79  This suggests that the true burden of liver cancer in Egypt 
has yet to be realized. 
 
SUMMARY AND SPECIFIC AIMS 
Though the studies mentioned above have contributed greatly to our 
understanding of the gravity of the problem in Egypt, they are lacking a more quantitative 
approach that would provide the data necessary for developing appropriate health policy.  
Such data would also be useful in making geographic comparisons, either across regions 
in Egypt and the Arab world or on a global scale.  This dissertation offers a series of 
studies designed to precisely define the nature of hepatitis virus infections and HCC in 
Egypt, spatially and temporally, as well as their future implications.  This approach is 
necessary to disentangle the complex etiology of liver disease in Egypt and the web of 
confounders often produced by qualitative assessment of exposures. 
   In this dissertation, specific aims were to: 
1) Characterize the descriptive features of HCC cases in the Nile Delta through  
extensive examination of Egypt’s only population-based cancer registry for the 
period 1999-2003.  This study represents the first population-based HCC study in 
Egypt. 
2) Determine if heterogeneous spatial patterns in HCC cases exist in the Nile 
Delta and if these spatial patterns can be linked to those of squamous cell 
carcinoma of the bladder.  This retrospective analysis addresses: 1) the question 
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of heterogeneity among HCC risk factors; and 2) the relationship between PAT 
treatment, HCV transmission, and HCC incidence.   
3) Determine time trends and other descriptive elements of HBV and HCV 
infections among the healthy population and HCC cases in Egypt by means of a 
systematic literature review and meta-analysis for the period 1980-present.  
4) Calculate prior HCV incidence in Lower Egypt (Nile Delta) using age-specific 
sero-prevalence data, and estimate the future health burden due to HCV sequelae 
using a Markov natural history model. 
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Figure 1.1. Anatomy of the liver.7 
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PATTERNS OF HEPATOCELLULAR CARCINOMA INCIDENCE IN EGYPT 




Liver cancer rapidly reduces quality of life and typically causes death within six 
months to one year from diagnosis.1  Globally, it is the fifth leading cause of cancer and 
the third leading cause of cancer deaths.1-2  This cancer varies widely in incidence 
throughout the world with rising incidence in Egypt.  The primary risk factors for 
hepatocellular carcinoma (HCC) are hepatitis B virus (HBV), hepatitis C virus (HCV), 
dietary aflatoxin exposure, and chronic alcohol consumption. 1-2   
Prior to the introduction of the HBV vaccine, chronic infection with HBV was generally 
high, with developing countries sharing the greatest burden.3  Consequently, HBV was 
the dominant etiologic factor in the development of HCC.  This is largely still true in 
Egypt, because vaccination programs were not started until the 1980s.  More recently, 
HCV has begun to eclipse HBV in incidence in many countries throughout North 
America, Europe, and the Middle East.4-5  Rates of HCV in Egypt are among the highest 
in the world, with a prevalence rate of up to 20%.6-7  Although an HBV vaccine program 
has been successfully implemented, with childhood coverage estimated at 95%-100%, 
most people born 20 years or more ago in Egypt have not been vaccinated.8-9  
 Hospital-based studies from Egypt have reported an overall increase in the 
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relative frequency of all liver-related cancers in Egypt (>95% as HCC), from 
approximately 4.0% in 1993 to 7.3% in 2003.10  Recent investigations in Egypt have 
shown the increasing importance of HCV infection in the etiology of liver cancer, 
estimated to account for 40-50% of cases, and the declining influence of HBV and 
HBV/HCV infection (25% and 15% respectively).10-12 
Few studies in Egypt have fully measured the presence of aflatoxins and their 
impact on liver disease there.  A recent study by Rahman el-Zayadi et al. examined 200 
HCC cases and 120 healthy controls, and detected aflatoxin B(1) in 17% of the HCC 
cases compared to 9.4% of the healthy controls (risk ratio = 2).13  In 2005, Sayed et al. 
performed a cross-sectional analysis on risk factors for liver disease in a rural population 
south of Cairo to evaluate aflatoxin exposure in serum.14  They found aflatoxin B(1) to be 
associated with hepatits B virus s antigen (HBsAg) seropositive subjects (odds ratio = 
6.2) and anti-HCV seropositive subjects (odds ratio = 2.5).14     
In addition to HBV, HCV and aflatoxins, other risk factors have been linked to 
HCC, including chronic alcohol consumption and hemochromatosis.  Although alcohol 
plays a significant role in the etiology of HCC in many countries, it was not examined in 
this study because the prevalence of alcohol consumption in Egypt is extremely low.15-16  
Hemochromatosis also was not investigated in this study, because in Egypt it is extremely 
rare.17-18  
With assistance and quality assurance from the United States NCI, Egypt 
successfully created a population-based cancer registry in Gharbiah province (Figure 2.1) 
that has been successfully functional since 1999.19  The first year of the registry data 
(1999) showed that the age-standardized annual incidence rate of HCC was 
 26
~20.6/100,000 in males and ~5.2/100,000 in females.  A comparison of data from the 
Gharbiah Population-based Cancer Registry (GPCR) for the period 1999-2001 with other 
countries in the Middle East Cancer Consortium showed that the liver cancer incidence 
rate was 7 times greater than the next-highest country rate, and more than 3 times the rate 
reported by United States Surveillance Epidemiology and End Results (SEER).19  Our 
study was designed to characterize the demographic and geographic patterns of HCC 
cases in this region to lay the groundwork for future research directed at understanding 
the complex etiology of this disease.  Accordingly, we retrieved and analyzed data of all 
HCC patients included in the GPCR from January 1, 1999 through December 31, 2003.  
We analyze the demographic and geographic characteristics of HCC patients and 




 Characteristics of the Study Region.  Gharbiah Province is located in the 
middle of the Nile delta, approximately 100 km north of Cairo.  The province population 
(4.2 million people - 5.7% of Egypt) has a density of ~1,752/km2, making it the tenth 
most densely populated province in Egypt (Egypt has a total of 27 provinces).  The 
male:female ratio in the Gharbiah province is 1.02:1, and the age structure resembles that 
of the rest of the country, with 47% of the population <20 years and 3.6% >65 years.20  
Gharbiah Province is considered an urban-rural Province by the Central Agency for 
Public Mobilization and Statistics (CAPMAS) with 31% of the population in urban areas 
and 69% in rural areas. 20  Each of its 8 districts has its own main city.  The capital of 
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Gharbiah Province is the city of Tanta, which serves as the headquarters for the 
population-based cancer registry.  Gharbiah has a total of 316 villages, and is mainly 
agricultural, but one district (El Mehalla) is a major textile producer in Egypt.  Annual 
incidence rates of HCC were based on population data estimated using linear 
interpolation between pairs of published government census population information.  
This preliminary study used an annual linear interpolation from the 1996 census data, and 
the 2001 and 2005 population projections. 20 
Gharbiah Population-Based Cancer Registry Data.  The GPCR was 
established in 1998 as part of the Middle East Cancer Consortium (MECC) Joint Cancer 
Registration Project, and it is affiliated with the Egyptian Ministry of Health and 
Population.21  The registry actively seeks all cases in Gharbiah province, regardless of 
inpatient/outpatient status or whether patients were seen in public or private hospitals.  
Information is gathered from medical records of government and private hospitals and 
clinics, death certificates, and histopathology laboratories and radiology clinics.  A team 
of registrars trained by the International Agency for Research on Cancer (IARC) and 
Emory University School of Public Health in Atlanta, USA conduct regular visits with 
each collaborating center to obtain the data and review its quality using IARC’s standard 
review process.  Data quality was assessed in 2002 for completeness of coverage and 
reliability of registration.  In addition to computer checks through CanReg software; 
external auditing was done by Emory University staff in 2002.  Coverage was found to 
exceed 90% of the Gharbiah population.22 
The registry conducts routine data cleaning by standardizing field entries and 
removing duplicate entries.  Inconsistencies were addressed by reviewing medical 
 28
records.  We obtained the data of all liver cancer cases diagnosed and included in the 
registry from January 1, 1999 through December 31, 2003 (n = 1,309).  Our case 
definition was restricted to those with an ICD-10 topology code of 22.0 and a 
morphology of HCC.  Cases were excluded if they did not satisfy both elements of the 
case definition or if they had missing values and if inconsistencies were not resolved after 
examining medical records.  This process reduced the total number of cases to 1,186 
(removing 123 cases).  The following variables were obtained for each case: registry 
patient number, sequence number, age at diagnosis, date of birth, gender, usual 
residential address, date of diagnosis, basis of diagnosis, primary site code (ICD-O-3), 
morphology codes, histology type, behavior, grade/differentiation/cell indicator, and 
summary stage at diagnosis.  Additional variables included: family history, marital status, 
smoking history, religion, occupation, and treatment data.  Unfortunately hepatitis data 
are not currently included in the management protocol for HCC cases at the GPCR.  
Thus, patient HBV and HCV status were unavailable for this study.  Additionally, 
because this study was retrospective and the cases in our sample were all deceased, there 
was no way to independently acquire HBV/HCV data. 
Statistical analyses.  The annual and average age- and sex-specific incidence 
rates for the period 1999-2003 were calculated using the number of HCC cases as the 
numerator and age-sex-specific population data from Egypt as the denominator.  
Univariate analyses were used to develop a descriptive profile for cases, using 
demographic indicators and information regarding the case's geographic location of 
residence at the time of diagnosis.  Interannual variation in number of cases during the 
five year period in Gharbiah and in individual districts was examined using chi-square 
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analyses.  Rate ratios (RR) were calculated to examine the differences among the eight 
districts of Gharbiah.  We also calculated and compared the incidence rates for HCC 
among cases residing in urban and rural regions of Gharbiah. 
We also compared HCC incidence rates for the years 1999-2003 in Gharbiah to 
those for 1999-2002 from United States SEER.23  Age-specific incidence rates for 
Gharbiah and the United States were adjusted to the World million, and age-adjusted 
rates of the two regions were compared.24  Rate ratio (RR) estimates and 95% confidence 
intervals (CI) were used to estimate age-specific incidence variation between Gharbiah 
and the United States.  All statistical operations were conducted using SAS software, 
version 9.1 (SAS Institute, Inc., Cary, NC. 2006).  
Ethical Oversight.  Our study protocol was approved by Internal Review Boards 
at the University of Michigan and the registry ethical committee in Egypt.  
 
RESULTS 
Incidence and descriptive features of HCC.  The number of HCC cases 
registered in the GPCR from 1999 through 2003 was fairly stable over the five-year study 
period, with 200-250 cases per year (Table 1).  Cyto-histopathological confirmation of 
the primary tumor was the basis of diagnosis in 33.5% of cases.  Non-microscopic 
(laboratory marker/radiological) diagnosis was the basis of diagnosis in 43.2% of cases.  
Approximately 23% of cases were diagnosed by death certificate only.  The majority of 
cases (96.5%) were aged 40 years and older.  Of the 1,186 HCC cases, 949 (80%) were 
males and 237 (20%) were females.  Males had consistently higher incidence rates than 
females for all age groups above 40 years (Table 2). 
 30
Geographic patterns in incidence among districts.  Geographically, 1,062 cases 
(89.5%) reported being born in Gharbiah, supporting the notion that the population in this 
region is fairly stable and suggesting that relevant exposures largely occurred in 
Gharbiah.  The eight districts varied considerably in population, representing the 
following percentages of the total provincial population: Tanta - 23.9%, El Mehalla - 
22.6%, Kafr El Zayat - 8.7%, Zefta - 9.7%, El Santa - 9.2%, Samanoud - 7.4%, Kotour - 
7.2%, Basyoon - 6.3%.20  In addition to being the most densely populated districts, Tanta 
and El Mehalla jointly account for approximately 56.4% of the cases in the registry.  The 
remaining six districts, however, did not all contribute cases in relative proportion to their 
population densities.  Interannual variation in number of cases during the five year period 
in Gharbiah and in individual districts was examined using chi-square analyses.  No 
significant differences were found except in Zefta (P = 0.01; not shown), which had more 
cases diagnosed in 2000 than in any other year. 
A similar proportion of cases came from rural and urban regions of the 
governorate, accounting for 50.7% and 49.3% respectively.  However, mean age-adjusted 
incidence rates were greater for cases residing in urban (15.8/100,000PY) than in rural 
(8.6/100,000PY) areas.  Urban residents had an incidence rate 1.84 times greater than that 
among rural residents (95% CI 1.42, 3.13). 
The mean age-adjusted incidence rates for HCC in Gharbiah and its eight districts 
for males, females, and the total population (1999-2003) also varied (Table 3; Figure 
2.2).  Chi-square analysis of the HCC incidence rates of the 8 districts showed 
statistically significant variation (p < 0.0001), largely the result of variation among males 
(P < 0.0001).  Overall, Kotour had the highest incidence rates among males and the total 
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population (24.1/100,000PY and 12.9/100,000PY respectively), with Samanoud having 
the lowest rates (10.3/100,000PY and 6.1/100,000PY respectively).  Incidence rates 
among females showed a different distribution, with the highest occurring in Tanta and El 
Mehalla (5.8/100,000PY) and the lowest in Zefta (1.5/100,000PY).  Statistically 
significant differences were not observed among females, likely a result of small sample 
size and insufficient power. 
The RRs for HCC incidence rates among the eight districts varied considerably 
(Table 4).  Among the largest RRs were those of Kotour compared with Samanoud (2.34 
times greater) and Kotour compared with Zefta (1.94 times greater).  People in Tanta had 
1.94 times the rate of HCC as those in Samanoud.  Other significant rate ratios varied 
between 1.29 and 1.85. 
Comparisons between incidence rates in Gharbiah versus the United States.  
Our results showed that the overall age-adjusted HCC incidence rate in Gharbiah  
(10.6/100,000) is significantly higher than the rate observed in the United States 
(3.0/100,000), with a rate ratio of 3.53 (95%CI 3.11, 4.67).  Incidence rates among males 
were significantly higher than those among females in both Egypt and the United States.  
Males in Egypt had incidence rates 4.3 times higher than females (95%CI 3.11, 5.66), 
and males in the United States had rates 3.3 times higher than females (95%CI 3.16, 
4.34).  In addition, age-specific incidence rates were significantly higher in Egypt 
compared to the United States for all age groups older than 40 years (Table 5).  
Significant differences in rates among the younger age groups were not apparent.  These 




Analyses from this population-based cancer registry were based on HCC cases 
that appear to be largely complete and highly representative.  Case data from the GPCR 
were obtained from virtually all sources in the province, and there is no reason why 
agencies from various sectors would not have participated in the registry.  GPCR is 
financially and scientifically supported by the United States National Cancer Institute, 
and has quality assurance from SEER and the International Association of Cancer 
Registries.  Standard procedures for training registrars and for data collection, processing, 
and transmission enhanced the accuracy of data.  In addition, the population-based 
structure improves our ability to draw conclusions about the entire province from the 
study results.  For these reasons, our study is unlike other hospital- or clinic-based reports 
that have previously appeared for HCC in Egypt, as it includes essentially all cases in the 
study area.  Thus, results represent a high degree of internal and external validity.  
Furthermore, data on the vast majority of cases included complete demographic and 
geographic information.  It is reassuring that the number of HCC cases reported per year 
did not vary during the five years of this study.  Therefore, the case data that we analyzed 
should be considered valid for the populations at risk, and the results generalizable at 
least to the people of Gharbiah Province.   
At first glance, the approximately 23% of cases diagnosed using only the death 
certificate might seem overly high.  This percentage, however, is not unusually high for 
liver cancer.1  Due to difficulty in diagnosing HCC even in developed countries, many 
cases are not diagnosed until death.1,25  This is more a limitation of current technology 
than specific registry methods.  In fact, the overall proportion of cancers diagnosed by 
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death certificate only in the Gharbiah registry is only 6-7%.  It is also unlikely that 
missed cases would significantly alter our findings.  The GPCR has a reported coverage 
rate of greater than 90% for Gharbiah province.22  The number of cases could be 
underestimated due to HCC being misclassified as cirrhosis, but there is no reason to 
believe that this underestimation is biased in any way.  Access to healthcare is similar 
across the province, and there is nothing to suggest that physicians diagnose differently in 
any systematic way.   
This study presents various findings that are similar to, but also different from, 
those that have previously addressed HCC in the Middle Eastern region.  As has been 
shown consistently in other studies, male incidence was considerably greater than that for 
females.  Worldwide, estimates show males to be 1.3 to 3.6 times as likely to develop 
HCC as females.1  In high-risk countries, sex ratios tend to be higher, and this is 
demonstrated here by the lower rate ratio seen in the United States versus Egypt.  A 
satisfactory biologic interpretation has yet to be demonstrated.  Several hypotheses have 
been investigated, however, including the interaction of sex hormones with HBV, leading 
to a different natural history depending on the sex of the individual, or the impact of sex 
specific exposures.26-27 
Interestingly, the incidence rate of HCC in Gharbiah was 3.5 times higher than 
that reported in the United States.  Such results were seen in the overall age-adjusted 
incidence rates, as well as the age-specific rates in age groups older than 40 years, among 
both males and females.  This finding expands upon reports in the United States NCI and 
MECC publications for a shorter period, 1999-2001.19  Our similar findings for a longer 
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period suggest that variation in rates truly reflect different risk factor profiles of these two 
populations, warranting further prospective studies. 
The most notable finding of this study, however, was the statistically significant 
geographic variation in incidence of HCC among districts within Gharbiah province.  
Incidence ranged from 12.9/100,000PY (Kotour) to less than half that rate at 
6.1/100,000PY (Samanoud).  Districts were similar with respect to age distribution and 
sex-ratios, suggesting that the at-risk populations were fairly homogeneous.  
Consequently, this observed heterogeneity is likely attributable to variation in local risk 
factors that future studies may investigate. 
Another interesting finding demonstrated HCC incidence among urban 
individuals was nearly twice that of rural residents.  Several studies have postulated that 
the HCV epidemic in Egypt has disproportionately affected rural populations, which 
should be reflected in the distribution of HCC cases.28-29  The HCV epidemic in Egypt is 
unique.  Egypt developed the world’s highest rates of HCV infection over a short period 
of time, largely due to a massive public health campaign.  The vast majority of infections 
among individuals age 30 years and older can be explained by parenteral anti-
Schistosomal therapy (PAT) and other iatrogenic exposures.29-32  The anti-
Schistosomiasis campaign extended from the 1950's through the 1980's, with peak 
transmission probably occurring during the 1960's and 1970's.  In 1982, praziquantal, an 
oral treatment for Schistosomiasis, was introduced, and use of PAT declined.  Since 
Schistosomiasis was a greater problem in rural regions, these populations were more 
affected by the PAT campaign, and, consequently, HCV transmission.30,32  With 
iatrogenic infections nearly eliminated, person-to-person transmission is presently the 
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dominant route, which should preserve the urban/rural disparity.  Higher rates of HCV 
infection should manifest as higher rates of HCC. 
The higher HCC incidence among urban residents could represent better access to 
medical facilities, resulting in an underestimate of HCC in rural populations.  It is also 
possible that the peak of the cohort with PAT-related HCV transmission has not yet 
matured, suggesting the incidence of HCC due to HCV is still increasing and competing 
with HBV-related HCC incidence.  This could mean a shift in burden from urban to rural 
regions is currently underway and will be discernible in the near future.  It should also be 
noted that disease progression from HCV to HCC may take up to 20 years and the 
incidence of HCC can increase in both urban and rural area in Egypt over the next years.  
Risk factors of most importance in this region include hepatitis B virus, hepatitis C virus, 
and dietary aflatoxins.  Unfortunately, we were unable to acquire data on the HBV and 
HCV status of our cases, as testing is not standard protocol for patient intake and 
management at the GPCR.  Due to the retrospective nature of our study, we were unable 
to independently test cases, as they were all deceased at the time of study initiation.  
Nevertheless, several studies in Egypt have documented general prevalence of HCV and 
HBV throughout the country, and we can use these results to help guide our inference. 
Several small-scale hospital-based studies have been conducted to examine the 
etiologic significance of the primary HCC risk factors in Egypt, though it should be noted 
that they have not assessed geographic variation.  These studies have shown the 
increasing importance of HCV in liver cancer, estimated to account for 40-50% of liver 
cancer cases, and the declining influence of HBV and HBV/HCV infection, 25% and 
15% respectively.10-12  These studies also have documented an overall increase in the 
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relative frequency of liver cancer in Egypt, from approximately 4.0% in 1993 to 7.3% in 
2003.10  Such increase in liver cancer is generally attributed to HCV.   
Since chronic HCV does not typically lead to carcinogenesis for 10-30 years 
following infection, the rates of liver cancer can be expected to continue increasing until 
the cohort of PAT-related infected individuals has worked its way through.10,29  This 
suggests that the true burden of liver cancer in Egypt has yet to be realized. 
Data on schistosomiasis infection in these cases were unavailable.  While the role 
of hepatic schistosomiasis has long been controversial, the prevailing view today is that it 
has limited influence in the etiology of HCC in Egypt.  Epidemiological studies of HCC 
clearly identified HBV, HCV or HBV/HCV co-infection as important, but 
schistosomiasis could not be identified as a statistically significant independent risk 
factor.19,33  For these reasons, we do not feel the lack of schistosomiasis infection data 
influence our conclusions.  
As in many developing countries, Egypt is undergoing an epidemiologic 
transition.  With increasing urbanization, smoking rates, environmental exposures, and 
aging, in addition to the maturing HCV epidemic, it is likely that HCC will continue to 
rise for the next few decades. Therefore, further studies to assess the magnitude and risk 
factors of HCC in Egypt and other developing countries seem warranted.  Our study 
produced important preliminary insights that can be used to develop more refined, 
prospective analyses of HCC risk in Egypt.  Ongoing collaborations are building upon 
these preliminary findings to develop studies that will examine cases from the point of 
intake and acquire HBV/HCV test results to expand our inference regarding the relative 
importance of certain risk factors on HCC in Egypt.  Such analysis should help define the 
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complex etiology of HCC, enabling policy makers to create targeted, more efficient 
prevention programs. 
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Table 2.1.  Characteristics of people diagnosed with hepatocellular carcinoma in 
Gharbiah, Egypt during 1999 through 2003. 
 








































Region of Residence Tanta 
El Mehalla 











































Basis of Diagnosis Microscopic 
Non-Microscopic 







* N = 1,185; missing birth place information for one patient 
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Table 2.2  Comparison of mean age-specific incidence rates of hepatocellular carcinoma 

















RR males vs. females 
(95% CI) 
     
0-24 0.6 0.4 0.4 0.3 1.42   (0.03, 56.1) 
25-29 0.6 0.5 0.2 0.1 3.30   (0.02, 161.0) 
30-34 1.0 0.8 1.4 1.1 0.73   (0.1, 13.8) 
35-39 2.2 1.8 1.6 1.3 1.42   (0.2, 9.1) 
40-44 10.0 9.4 2.2 2.1 4.40   (1.0, 8.7) 
45-49 19.4 21.0 4.0 4.8 4.37   (1.5, 7.3) 
50-54 30.4 48.1 7.2 11.3 4.24   (1.9, 6.5) 
55-59 35.8 73.8 8.8 19.2 3.85   (1.8, 5.9) 
60-64 36.0 86.0 6.4 13.9 6.19   (2. 7, 8.5) 
65-69 23.2 75.6 6.0 19.7 3.84   (1.6, 6.3) 
70-74 19.4 101.5 6.8 31.5 3.22   (1.3, 5.6) 
75 + 14.8 105.2 2.2 13.6 7.76   (1.9, 11.9) 
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Table 2.3.  Mean age-adjusted incidence rates per million for hepatocellular carcinoma in 
Gharbiah, Egypt and its districts per 100,000 PY (1999 through 2003).  Rates 











Gharbiah (all) 16.7 4.0 10.6 
Kotour 24.1 3.3 12.9 
Tanta 19.9 5.8 12.3 
El Mehalla 18.4 5.8 12.1 
Kafr El Zayat 19.0 3.7 11.1 
Basyoon 17.9 3.2 10.4 
El Santa 15.4 2.6 8.8 
Zefta 12.5 1.5 6.9 




Table 2.4.  Mean incidence rate ratios for hepatocellular carcinoma among the districts of 
Gharbiah per 100,000 PY (1999-2003).  Rate Ratio = (Row District / Column District).  
95% confidence limits are given in parentheses. 
 




Basyoon El Santa Zefta Samanoud 





























Basyoon     --- NS 1.43 (1.02, 2.01) 
1.74 
(1.17, 2.58) 
El Santa      --- NS 1.50 (1.02, 2.19) 
Zefta       --- NS  
Samanoud        ---  
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Table 2.5.  Age-specific Egyptian HCC incidence rates for 1999 through 2003 compared 















0-24* --- --- --- --- 
25-29 0.3 0.3 1.10 0.12, 10.21 
30-34 1.0 0.5 2.09 0.57, 7.66 
35-39 1.6 0.6 2.47 0.89, 6.87 
40-44 6.1 1.8 3.37 1.90, 5.96 
45-49 13.9 5.2 2.70 1.79, 4.06 
50-54 31.2 7.3 4.28 3.10, 5.93 
55-59 49.7 8.9 5.58 4.14, 7.53 
60-64 51.1 11.9 4.28 3.10, 5.93 
65-69 50.1 16.5 3.05 2.11, 4.39 
70-74 67.8 19.6 3.46 2.35, 5.08 
75 + 39.1 18.3 2.14 1.19, 3.85 
Total 10.6 3.0 3.53 3.11, 4.02 








Figure 2.2.  Mean age-adjusted incidence rates for hepatocellular carcinoma in the eight 
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SPATIAL ANALYSIS OF HEPATOCELLULAR CARCINOMA IN EGYPT: 





Primary liver cancer (PLC) ranks fifth worldwide in incidence of cancers, with an 
estimated 0.5 to 1 million cases diagnosed each year, and third in cancer mortality.1-2  In 
developing countries, however, it often ranks as the leading cause of cancer incidence 
and mortality among males.  Hepatocellular carcinoma (HCC) is by far the dominant 
PLC malignancy and has the greatest relevance to public health.  Reports of rising HCC 
incidence in many countries throughout the world frequently cite increased burden of 
hepatitis C virus (HCV) and synergistic interactions among risk factors as contributing 
causes.1-2  Risks for HCC are most often associated with hepatitis B virus (HBV), 
hepatitis C virus (HCV), dietary aflatoxin exposure, and chronic alcohol consumption.1   
Hepatocellular carcinoma in Egypt is currently undergoing a shift in the relative 
importance of HBV and HCV as primary risk factors.  Prior to implementing HBV 
vaccine in the 1980s, chronic infection with HBV was widespread and considered the 
dominant etiologic factor in HCC development.3  Childhood HBV immunization in Egypt 
today is estimated at 95% to 100%, thus making it likely that HBV-related HCC will 
steadily decline over the next few decades.4-5  Despite this major public health 
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achievement, HCC continues to be the second highest cancer incidence and mortality 
among Egyptian men.  Hospital-based studies from Egypt have even reported an overall 
increase in the relative frequency of all liver-related cancers in Egypt (>95% as HCC), 
from approximately 4.0% in 1993 to 7.3% in 2003.6-8  Recently, the Middle East Cancer 
Consortium reported that the incidence rate among males was seven times greater than 
the next highest rate (among Israeli Jews) and more than three times that reported in the 
United States Surveillance Epidemiology and End Results (SEER) summary.9   
The future of HCC in Egypt will be a legacy of its unique HCV epidemic.  Egypt 
boasts the highest prevalence of hepatitis C virus (HCV) in the world.10-11  Egypt 
developed the world’s highest rates of HCV infection over a remarkably short period of 
time, with a prevalence rate of up to 20%. 10-11  Most infections among individuals age 30 
years and older occurred through widespread use of inadequately sterilized needles for 
administering parenteral anti-schistosomal therapy (PAT), and through other iatrogenic 
exposures.12-15  The anti-schistosomiasis campaign took place during the 1950s through 
the 1980s, with peak HCV transmission probably occurring during the 1960s and 
1970s.13,15  An equal number of people were infected with HBV and HCV during the 
PAT campaign; however, HBV only caused chronic infections in approximately 5% of 
infected individuals, whereas chronic HCV infection developed in 70% to 80%.13,15  This 
is a function of the natural history of HBV, where the probability of developing chronic 
infection decreases with age.2-3  Since most individuals receiving PAT were 10-15 years 
or older, they were at lower risk for developing persistent HBV infection.15   
Despite the introduction of an oral treatment in 1982 followed by the elimination 
of the PAT program, HCV transmission persists.  Hepatitis C virus infection is assuming 
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increasing importance in the etiology of liver cancer in Egypt, and is estimated to account 
for 40 to 50% of cases, overtaking the influence of HBV and HBV/HCV infection (25% 
and 15% respectively).6-8   
Geographic variation in HCC incidence in Egypt has not been studied.  Some 
reports have made simple comparisons between upper and lower Egypt or between urban 
and rural populations with respect to presumed exposures, but results have been 
limited.16-19  More detailed, formal spatial analysis of HCC could be instrumental in 
identifying areas of high risk and assisting health policy makers to more efficiently 
allocate resources.  Quantifying the current spatial distribution of HCC in Egypt is 
important to understanding the ongoing transition of primary risk factors.  Current 
distributional data offer a baseline documenting the beginning wave of HCC cases 
resulting from PAT treatment.  Future surveillance can then track spatial trends in HCC 
incidence, potentially revealing the underlying dynamics of HCV transmission.   
Accordingly, we analyzed data collected from 1999 through 2003 by the Gharbiah 
Population-based Cancer Registry (GPCR) in Gharbiah Province, Egypt in an effort to 
determine whether spatial variation in HCC incidence exists and whether such variation 
could be linked to certain environmental factors.  We specifically looked at factories and 
irrigation drainage canals, which could indicate sources of environmental pollutants.  We 
also examined the spatial distribution of squamous cell carcinoma of the bladder in 
relation to that of HCC.   
Despite extensive searches and inquiries, we were unable to identify any sources 
of PAT distribution data, necessitating the use of a proxy measure.  Squamous cell 
carcinoma of the bladder (SCC-B) is most often attributed to chronic schistosomiasis 
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infection.  In Egypt, chronic schistosomiasis has been estimated to account for more than 
95% of all SCC-B cases.20-21  We hypothesized that spatial variation in both cancers 
might be similar within this registry cohort, because the cohort represents people heavily 
burdened by schistosomiasis also also previously exposed to the PAT campaign.  Areas 
with higher rates of schistosomiasis may have received more exposures to HCV through 
PAT treatment, resulting in higher rates of HCC (see Figure 3.1 for a conceptual model).  
These same high-schistosomiasis areas should also have more SCC-B.  An overlap in 
spatial patterns of the two cancers would suggest pathways involving schistosomiasis, 
PAT, and HCV for HCC, and schistosomiasis for SCC-B.   
 
METHODS 
Characteristics of the Study Region.  Gharbiah Province is located in the 
middle of the Nile delta, approximately 100 km north of Cairo (Figure 3.2).22  Population 
density is tenth among the 27 Provinces in Egypt with 4.2 million people (5.7% of 
Egypt’s population).  The age and sex structure do not differ significantly from the 
national average.  The male:female ratio is 1.02:1, and 47% of the population is younger 
than 20 years of age.23  Gharbiah is considered an "urban-rural" Province by the Central 
Agency for Public Mobilization and Statistics (CAPMAS), with 31% of the population in 
urban areas and 69% in rural areas. 23  The Province has 317 villages/cities located within 
8 districts, each with a capital city.  The capital of Gharbiah Province is the city of Tanta, 
which serves as the headquarters for the GPCR.   
Gharbiah Population-Based Cancer Registry Data.  The GPCR was 
established in 1998 as part of the Middle East Cancer Consortium (MECC) Joint Cancer 
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Registration Project, and it is affiliated with the Egyptian Ministry of Health and 
Population.24  The registry uses active case finding, including investigating hospitals in 
other provinces for cases that reside in Gharbiah.  Information is compiled from medical 
records (government and private hospitals and clinics), death certificates, and 
histopathology laboratories and radiology clinics.  Registrars have been trained by the 
International Agency for Research on Cancer (IARC) and Emory University School of 
Public Health in Atlanta, USA, and they conduct regular visits with each collaborating 
center to obtain case data and review its quality according to IARC’s standard review 
process.  The registry conducts routine data cleaning by standardizing field entries and 
removing duplicate entries.  Data quality was assessed in 2002 for completeness of 
coverage and reliability of registration.  In addition to computer checks through CanReg 
software, external auditing was done by Emory University staff in 2002.  Coverage was 
found to exceed 90% of the Gharbiah population.25   
We obtained data for all liver cancer cases diagnosed and included in the registry 
from January 1, 1999 through December 31, 2003 (n = 1,309).  We restricted our case 
definition to those with an ICD-10 topology code of 22.0 and a morphology of HCC.  We 
also obtained data for all bladder cancer cases diagnosed and included in the registry 
from January 1, 1999 through December 31, 2002 (n = 1,209); review of 2003 data was 
not final at the time of data collection.  For bladder cancer, our case definition was 
limited to those with an ICD-10 topology code of 67.0 and a morphology of squamous 
cell carcinoma (n = 256).  For both cancers, cases were excluded if they did not satisfy 
both elements of the case definition or if they had inconsistencies or missing values that 
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would not be resolved by examining medical records.  This selection process resulted in 
1,186 (92.4%) HCC cases and 256 (100%) SCC-B cases that were analyzed. 
Variables obtained for each case included: registry patient number, age at 
diagnosis, date of birth, gender, usual residential address, date of diagnosis, basis of 
diagnosis, primary site code (ICD-O-3), morphology codes, histology type, behavior, 
grade/differentiation/cell indicator, and summary stage at diagnosis.  Additional variables 
included: family history, marital status, smoking history, religion, occupation, and 
treatment data.  Unfortunately, data on patient HBV and HCV status were unavailable, as 
these tests are not routinely done.  Because of the retrospective nature of this study, and 
because most of the cases in our sample are deceased, it was not possible to 
independently acquire HBV/HCV data. 
Population and Geographic Data.  Population abundances were estimated using 
annual linear interpolation from the 1996 Egypt census and the 2001 population 
projections, and then the 2001 and 2005 projections.  Census data were available at the 
village level and provided age- and sex-specific population counts.   
Geographic data were obtained after digitizing maps from the Egyptian General 
Survey Authority.  Centroid coordinates (latitude, longitude) were acquired for all 
villages and factories in the Province.  In addition, we calculated the shortest distance 
between each village centroid and its nearest drainage canal.  All mapping and 
visualization was done using ArcGIS (version 9.1, ESRI, Redlands, CA). 
Statistical analyses: Case and Population Description.  We calculated mean 
annual age-sex-standardized incidence rates for HCC and SCC-B at the Province, district, 
and village levels.  We performed chi-square analyses to test for heterogeneity in 
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incidences across districts.  We also calculated rate ratios among males and females as 
well as urban and rural cases.  To determine comparability of villages for spatial analysis, 
we examined village population data for sex ratios and age structure. 
Statistical analyses: Environmental Associations.  We calculated the distance 
from each village to each factory and from each village to its nearest drainage canal.  We 
performed t-tests and chi-square tests to determine if there were any associations among 
HCC incidence and distance to factory, factory type, and/or drainage canal.  For the 
factory type analysis, each of the 29 factories was placed in one of the following 
categories: Textile, Agricultural, Industrial, and Water Treatment.   
Statistical analyses: Spatial Analysis.  Because different spatial analytical 
methods may identify different spatial patterns, we used two independent cluster 
detection methods to test our hypothesis that spatial clustering of HCC and SCC-B 
existed in Gharbiah Province.  Different methods with consistent results would increase 
our confidence in the robustness of our findings.  Therefore, we applied a spatial 
autocorrelation method and a spatial scan method and compared the results of local 
disease cluster patterns, using village centroid as the unit of analysis.  We used GeoDa 
software (version 0.9.5-I, Urbana-Champaign, IL) to generate Anselin’s Local Moran 
(LISA) test statistics for spatial autocorrelation.  The Local Moran statistic identifies 
locations (villages in this case) with disease rates statistically similar to and dissimilar 
from their neighbors.  The null hypothesis is one of no association in HCC incidence 
rates among neighboring villages.  The alternative hypothesis is that neighboring villages 
have similar rates, i.e. spatial clustering exists. 
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Because incidence rates for some health events can be unstable, reflecting 
sizeable variances, we applied Empirical Bayes (EB) smoothing to our raw HCC disease 
data.  This method adjusts village disease rates with respect to the overall mean of the 
study area.  This typically has its greatest impact on those villages with small population 
sizes.  We assigned spatial weights using the k-nearest neighbors method, selecting 9 
nearest neighbors after comparing weight results for 2 to 13 nearest neighbors.  Weights 
were consistent for 7 to 11 nearest neighbors.  We obtained Monte Carlo p-values based 
on 9,999 conditional randomizations.  We compared results for critical p-values ranging 
between 0.01 and 0.05.  We used an alpha level of 0.03 to limit statistical significance 
due to multiple comparisons. 
SaTScan software (version 6, Boston, MA) was employed to calculate scan 
statistics using the method described by Kulldorff (1997).26  This method involves 
moving a circular window around the study region.  At each central position of the 
window, the radius changes between zero and a user-defined upper limit.  For each 
window, the likelihood of finding the observed and expected number of cases inside the 
circle given the number of observed and expected cases outside of the circle is calculated.  
The null hypothesis is that the study region has a homogeneous incidence rate.  The 
alternative hypothesis is that at least one window contains an incidence rate significantly 
different from the mean Province rate. 
In this case, raw HCC data were used so as not to bias the likelihood ratio test 
statistic.  We assumed a Poisson probability disease model (case and population data).  
We examined the number of clusters detected by the method for the range 1 - 10km.  At 
7km, the number of clusters stabilized and remained the same through 10km.  
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Consequently, we selected 7km as the parameter value for our scanning window radius.  
Reported clusters were limited to those representing 20% or less of the population, 
though the initial test parameter was set at 50% to avoid bias.  As with the Moran test, 
calculations were based on 9,999 Monte Carlo randomizations.  Because the test already 
accounts for multiple testing, we used an alpha level of 0.05.   
To determine if the clusters found for HCC were statistically correlated with those 
found for SCC-B, we used the results from the spatial scan method.  We tested the 
conditional probability that village K is within 7km of a HCC cluster, given that village K 
is part of a SCC-B cluster.  We organized the data by distance to HCC or SCC-B clusters 
and identified all villages within 7km of a cluster.  We then translated the data into 
binomial distributions: villages in HCC clusters [0 = no; 1 = yes], village within 7km of 
SCC-B cluster [0 = no; 1 = yes].  This was done for high and low clusters separately.  We 
then used logistic regression to determine if HCC and SCC-B clusters tend to overlap 
more than we would expect by chance alone.  
Ethical Oversight.  Our study protocol was approved by Institutional Review 
Board at the University of Michigan and the registry ethical committee in Egypt. 
 
RESULTS 
Study population.  From 1999 through 2003, there were 1,186 cases of HCC and 
256 cases (through 2002) of SCC-B.  Table 3.1 presents the number of villages where the 
age-standardized incidence rates for HCC and bladder SCC-B are greater than zero.  
Overall, HCC was found in a greater proportion of villages than SCC-B.  For both 
cancers, Tanta was the district where the greatest proportions of villages have at least one 
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case (HCC = 90.4%; SCC-B = 48.1%), and Zefta was where the fewest proportion of 
villages had at least one case (HCC = 41.8%; SCC-B = 16.4%). 
The 5-year mean annual age-standardized incidence rate for HCC was 8.80 cases 
per 100,000 individuals, and the 4-year mean annual age-standardized incidence rate for 
SCC-B was 1.83 cases per 100,000 individuals.  District-specific mean annual age-
standardized rates are presented in Table 3.2.27  Chi-square tests found significant 
variation in incidence across districts for both cancers (p-values < 0.01; not shown). 
Overall, HCC and SCC-B were similar with respect to sex and urban/rural rate 
ratios.  Males had 4.13 (95% CI 3.58, 5.29) times the rate of HCC in females and 1.95 
(95% CI 1.50, 3.25) times the rate of SCC-B in females.  In addition, urban dwellers had 
1.83 (95% CI 1.63, 2.95) times the rate of HCC among rural populations and 1.76 (95% 
CI 1.35, 3.06) times the rate of SCC-B among rural populations. 
Examination of the population data revealed no significant differences among 
villages with respect to sex ratio and age distribution (not shown). 
Incidence rate maps.  Raw and EB smoothed incidence rates for HCC and SCC-
B are presented in Figure 3.3.  Villages with HCC are distinguished by breakpoints in 
incidence rates (per 100,000PY) as follows: zero, 0.1-19.9, 20.0-39.9, 40.0-59.9, and 
≥60.0.  Villages with SCC-B are distinguished by breakpoints in incidence rates (per 
100,000PY) as follows: zero, 0.1-4.9, 5.0-9.9, and ≥10.0.  The EB smoothed maps follow 
the same classification scheme to illuminate the impact of smoothing.  The EB smoothed 
map for HCC appears to show an overall pattern of higher risk in the western side of the 
Province and lower risk in the east.  There do appear to be areas of higher risk in the 
central northern and southern regions as well as the southwestern corner.  Note that the 
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process of smoothing rates eliminates the possibility of a village having a rate of 0.0 per 
100,000PY. 
Environmental Associations.  All tests for associations between HCC incidence 
and distance to factory, distance to factory type (Textile, Agricultural, Industrial, and 
Water Treatment), and distance to nearest drainage canal were not significant (not 
shown). 
Spatial clustering of HCC cases using GeoDa–Anselin’s Local Moran test 
(LISA).  Formal analysis using the Local Moran test identified significant HCC 
clustering in the Province (p-values < 0.03).  Three clusters of high risk were identified 
(Table 3.3; Figure 3.4a).  As we saw with the EB smoothed map, there were three 
primary clusters: the central northern region, the central southern region, and the 
southwestern region.  These correspond to the districts of Kotoor, Tanta, and Kafr El 
Zayat and their EB smoothed rates ranged: 5.2-7.82, 6.24, and 6.40-11.16 cases per 
100,000 individuals respectively.  (Note that because Anselin’s Local Moran tests each 
village against each neighbor individually, there are cases when a cluster may only 
contain one village.) 
In addition, three clusters of low risk were also significant (p-values < 0.03; Table 
3.3; Figure 3.4b).  These were located in the eastern area of the Province as would be 
expect based on the EB smoothed map.  These clusters correspond to the districts of El 
Mehalla El Kobra, Zefta, and Santa, and their EB smoothed rates ranged from 4.04-4.52, 
3.16-4.88, 2.76-5.14 cases per 100,000 individuals respectively. 
Spatial clustering of SCC-B cases using GeoDa–Anselin’s Local Moran test 
(LISA).  The Local Moran test identified two high risk (Table 3.3; Figure 3.5a) and three 
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low risk clusters for SCC-B (Table 3.3; Figure 3.5b).  The larger high risk region is also 
in the central northern region of the Province (Kotoor district) with EB smoothed rates 
ranging from 2.05-14.43 cases per 100,000 individuals.  The other high risk location was 
at a single point in El Mehalla El Kobra with an EB smoothed rate of 3.53.  All 
significant results reported had p-values < 0.03.   
The low risk areas also occurred in the eastern side of the Province save one that 
was located in the southwest corner (p-values < 0.03).  As with HCC, two of these 
clusters were focused in Zefta and Santa with EB smoothed rates ranging from 0.1-0.48 
and 0.05-1.20 cases per 100,000 individuals.  The other low risk area is centered in Kafr 
El Zayat, and the rates range from 0.18-0.93 per 100,000 individuals. 
Spatial clustering of HCC cases using SaTScan–spatial scan test statistic.  
Table 3.4 and Figures 3.4c and 3.4d show the results from the spatial scan statistic for 
HCC.  This method located 3 high risk regions and 4 low risk areas (p-values < 0.03).  
These correspond very closely with the clusters identified with the Local Moran method.  
The EB smoothed rates for the high clusters ranged: 4.84–11.18, 23.98, and 24.38 per 
100,000 individuals (1-3 respectively).  The EB smoothed rates for the 4 low clusters 
ranged: 2.04-4.26, 2.20-4.68, 1.22-3.12, and 1.58-6.76 per 100,000 individuals (1 to 4 
respectively). 
Spatial clustering of SCC-B cases using SaTScan–spatial scan test statistic.  
As with HCC, the spatial scan results for SCC-B corresponded quite well with those from 
the Local Moran test statistic.  Table 3.4 and Figures 3.5c and 3.5d present the results 
from the spatial scan statistic for SCC-B.  This method located 4 high risk regions and 4 
low risk areas (p-values < 0.03).  The EB smoothed rates for the high clusters ranged: 
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42.28, 3.86-11.54, 3.08-6.26, and 4.06 per 100,000 individuals (1 to 4 respectively).  The 
EB smoothed rates for the low clusters ranged: 0.04-0.34, 0.02-0.40, 0.06-0.54, and 0.2-
0.44 per 100,000 individuals (1 to 4 respectively). 
Spatial clustering of HCC and SCC-B cases.  Figure 3.6 displays the results 
from both the HCC and SCC-B cluster analyses together as layers, separated by high or 
low cluster as well as by type of statistical test used.  The most striking similarity that 
was seen among high-risk HCC and SCC-B clusters was the cluster in the central 
northern region of the Province (Kotoor district).  Both the Local Moran and spatial scan 
methods located clusters in that region, and they clearly overlap.  The scan method also 
located a high-risk cluster for HCC near a cluster for SCC-B in the central southern 
region of the Province.  There are a few other relatively small clusters for each cancer 
that do not overlap.  The dominant high-risk cluster for both cancers occurred in the same 
location. 
Low-risk clusters also showed a great deal of similarity between these two 
cancers.  Both have several clusters in the eastern region of the province.  In the 
southeastern region, corresponding with districts Zefta and Santa, there is significant 
overlap suggested by both methods of analysis.  The scan statistic also suggests some 
overlap may exist in the northeastern region, which corresponds to the district of El 
Mehalla El Kobra.  Among low risk clusters, only one SCC-B cluster did not overlap 
well with HCC clusters, in the southwestern region of the Province.  This is actually 
located near a high-risk cluster for HCC.   
Correlation between HCC and SCC-B clusters.  The logistic regression models 
we used were as follows:  
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(1) Village in a SCC-B low cluster = Village within 7km of a HCC low cluster; 
(2) Village in a SCC-B high cluster = Village within 7km of a HCC high cluster 
We found low clusters to be highly correlated with one another (P = 0.0010), and high 
clusters to be marginally correlated with one another (P = 0.0692). 
 
DISCUSSION 
Data Quality.  Our study is unique in comparison to other hospital- and clinic-
based reports that have previously been published for HCC in Egypt, as our analyses 
were based on HCC and squamous cell carcinoma of the bladder cases from a population-
based cancer registry and appear to be largely complete and highly representative.  GPCR 
is scientifically and financially supported by the United States National Cancer Institute, 
and it has quality assurance from US-SEER and the International Association of Cancer 
Registries.  Standard procedures for training registrars and for data collection, processing, 
and transmission enhanced the accuracy of data.  In addition, the population-based 
structure improves our ability to draw conclusions about the entire province from the 
study results. 
Our results represent a high degree of internal and external validity.  Data on the 
vast majority of cases included complete demographic and geographic information.  
There was little evidence of interannual variation in case reporting for either cancer for 
our study period, which was particularly reassuring.  In addition, external review of the 
data collected by the GPCR has found its coverage to exceed 90%, improving our 
confidence in accurate numerator estimates.25  Though it is possible the number of cases 
could be underestimated due to misclassification, there is no reason to believe that this 
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underestimation is biased in any significant way.  Access to healthcare is similar across 
the province, and there is nothing to suggest that physicians diagnose differently in any 
systematic way.  Therefore, we consider the case data that we analyzed to be valid for the 
populations at risk, and the results to be generalizable at least to the people of Gharbiah 
Province. 
Denominator estimates were based on census reports from 1996 and published 
census projections for 2001 and 2005.  We believe it was reasonable to calculate 
population estimates using linear interpolation, as this is a fairly stable population, 
experiencing the majority of its change through birth and death rates (low population 
mobility).  Data were available at the village level and age- and sex-specific values were 
provided.  We were unable to detect any significant differences between villages and the 
Province in aggregate with respect to age and sex distributions, suggesting that villages 
could be compared without serious concern for compromising our conclusions due to 
these important confounding variables.  We are confident that this increases the accuracy 
of our calculations, since both numerator and denominator data were available at the 
same high level of resolution. 
In addition, we based our spatial data on maps published by the Egyptian General 
Survey Authority, which followed international guidelines in the creation of their maps.  
A brief comparison of calculated point coordinates with those obtained from a handheld 
GPS unit for the same location suggested the maps were internally consistent and 
geographically accurate. 
Geo-spatial Results.  Significant variation among district-level incidence rates 
laid the foundation for more formal spatial analyses to test the hypothesis that HCC 
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spatially clusters in Gharbiah Province.  We applied two cluster detection methods that 
generate test statistics through independent means.  Both methods detected significant 
high- and low-risk clusters that were spatially similar, suggesting our results are indeed 
robust.  When combined with the fact that this population is quite stable and relatively 
homogeneous in terms of confounders, our findings suggest an underlying clustering of 
primary HCC risk factors.  
Risk factors of most importance in this region include hepatitis B virus, hepatitis 
C virus, and dietary aflatoxins.  Unfortunately, data on these risk factors were unavailable 
for our cases.  Testing for HBV and HCV is not standard protocol for intake at the 
GPCR, and a review of external medical records for a sample of cases revealed less than 
5% to have any test results reported.  This is understandable since most infected 
individuals do not experience symptoms and would have no reason to seek testing.  
Because our study was retrospective, we were unable to independently acquire risk factor 
data, as the cases were all deceased at the time of study initiation.   
Several studies in Egypt have documented general prevalence of these risk factors 
throughout the country, and we can use these results to help guide our inference.  Reports 
concerning HBV have suggested a relatively homogeneous geographic distribution of 
infection, with overall declining rates due to the successful implementation of the HBV 
vaccine.4-5  Studies examining HCV have shown higher levels of infection among 
residents in Lower Egypt versus those in Upper Egypt.6-7  Higher levels of HCV have 
also been observed in rural regions as opposed to urban areas. 6-7  Several studies have 
suggested that HCC is increasingly associated with HCV, and this trend is expected to 
continue as HBV rates decline. 6-8 
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Few studies in Egypt have fully measured the presence of aflatoxins and their 
impact on liver disease there.  Recent studies have documented p53 mutations associated 
with aflatoxin B(1) among HCC cases, as well as evidence of aflatoxin exposure in the 
serum of certain rural populations.16-17 
In addition to HBV, HCV and aflatoxins, other risk factors have been linked to 
HCC, including chronic alcohol consumption and hemochromatosis.  Although alcohol 
plays a major role in the etiology of HCC in many countries, it was not considered in this 
study because the prevalence of alcohol consumption in Egypt is extremely low.18-19  
Hemochromatosis also was not considered in this study, because in Egypt it is extremely 
rare.28-29 
There is also increasing interest in the role environmental contaminants may play 
in the development of HCC in Egypt.  Studies have shown exposure to pesticides and 
other chemicals to be associated with HCC in Egypt, often in conjunction with HBV 
and/or HCV infection.17-18  It is possible that these exposures may result in an additive 
interaction and subsequent increase in HCC risk.18   
To address this concern in an exploratory way, we examined the relationship 
between village-level HCC incidence and distance to factories and drainage canals.  
Factories can produce a great deal of contaminants that may be present in the air and 
water of the surrounding regions.  It is also likely that employees of the factories reside in 
nearby villages.  Drainage canals are another potentially point source for environmental 
contaminants.  These waterways receive the vast majority of water-related factory waste 
as well as any agricultural runoff (pesticides, etc).  We were unable to find any 
association between incidence and distance to possible environmental point sources.  This 
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does not necessarily reject the significance of such factors, but it may suggest that their 
underlying contribution to HCC burden is obscured by more dominant factors such as 
HBV and HCV.  
The common theme in the discussion of these risk factors is the tendency for them 
to be found in greater abundance in rural areas, which is contrary to our result of urban 
cases in Gharbiah having 1.83 times the rate of HCC versus rural cases.  The higher HCC 
incidence among urban residents could represent higher rates of HBV and/or HCV due to 
iatrogenic transmission during the etiologically relevant time period, which indeed has 
been documented.13,15  It is also possible that the peak of the cohort with PAT-related 
HCV transmission has yet to mature, suggesting the incidence of HCC due to HCV is still 
increasing.  This could mean a shift in burden from urban to rural regions is still ongoing 
and will be clearer in the near future.   
Hepatocellular carcinoma and squamous cell carcinoma of the bladder.  
Schistosomiasis has long been included in the discussion of HCC in Egypt.  There is little 
debate that its treatment was largely responsible for the creation of the HCV epidemic in 
Egypt, but its relationship with HCC is less clear.  Some hypothesize that its chronic 
presence in the human liver can increase risk for HCC, whether by active promotion or 
indirectly weakening the liver, reducing its ability to fight HBV and HCV.12,14  Still 
others believe schistosomiasis infection itself is not fundamental in liver carcinogenesis, 
but that the PAT campaign and resulting HCV epidemic is the true culprit.13   
Due to the limitations of our retrospective data set, we did not attempt to consider 
the specific mechanisms driving the relationship between schistosomiasis and HCC.  
Unfortunately, data on schistosomiasis infection as well as receipt of PAT among our 
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cases were unavailable despite extensive searches and inquiries.  Nevertheless, we 
hypothesized that if such a strong link existed between schistosomiasis and HCC, it 
should be reflected in the examination of the one type of cancer most associated with 
schistosomiasis of the urinary bladder: squamous cell carcinoma. 
Upon repeating our methods for the cluster analysis of HCC for squamous cell 
carcinoma, we again found significant high- and low-risk regions with strong agreement 
across the two methods.  In addition we found strong overlap in the primary high-risk 
cluster for both cancers as well as for all low-risk clusters except one for squamous cell 
carcinoma.  Our test for correlation between spatial clusters of HCC and SCC-B found a 
strong association among low clusters and a marginal association among high clusters.  
One possible explanation for why the low-risk clusters were better correlated than high-
risk clusters has to do with the interference, though admittedly intended purpose, of PAT.  
This was a treatment campaign, and it was successful with respect to schistosomiasis.  
Therefore, the regions with a high burden of schistosomiasis infection that received high 
frequencies of PAT resulted in a lower risk of chronic schistosomiasis and subsequent 
SCC-B.  Regions of already low risk for schistosomiasis would have received little PAT 
and, thus, little HCV-related transmission.  This scenario would explain the highly 
significant correlation in low-risk clusters and comparably less significance of high-risk 
clusters.  Data on schistosomiasis infection and PAT distribution for the etiologically 
relevant time period would be helpful in clarifying this picture, but, unfortunately, these 
data were not available. 
Though we do not suggest that all spatial variation in HCC can be explained by 
squamous cell carcinoma, the overlap present among the majority of clusters, which was 
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identified by two separate cluster detection methods, seems hardly a coincidence.  Of 
particular importance is the fact that this cohort of cases represents a population still 
burdened by schistosomiasis as well as the early wave of individuals affected by the PAT 
campaign.  We believe our findings support the strong connection between 
schistosomiasis and HCC, but more research is necessary to determine if the association 
is due to chronic schistosomiasis infection or exposure to PAT treatment. 
Conclusions.  Our study is the first to document spatial clustering of HCC cases 
in Egypt.  Spatial patterns of HCC did not seem to be influenced by environmental point 
sources of pollutants, but may be linked to the spatial distribution of squamous cell 
carcinoma of the bladder.  Our use of high quality population-based data in addition to 
rigorous statistical methods suggests our findings are highly robust.  Future studies 
should focus on the dynamics of HCC risk factors in order to better predict regions at 
greater risk for disease.  These initial spatial findings have already stimulated ongoing 
collaborations to begin developing studies that would include case enrollment and 
detailed risk factor data collection to improve inference regarding the relative 
significance of different risk factors in Egypt.  We hope these analyses will help untangle 
the complex etiology of HCC and assist policy makers in generating more efficient 
prevention and control programs. 
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Table 3.1.  Villages in Gharbiah (Total and by District): total number, number with age-
standardized incidence rates (ASR) greater than 0.0, and number with ASRs equal to 0.0. 
 
 # Villages # Villages  
HCC ASR > 0 
% Villages  
HCC ASR > 0 
# Villages 
SCC-B ASR > 0 
% Villages  
SCC-B ASR > 0 
Gharbiah 317 232 73.2 119 37.5 
      
Tanta 52 47 90.4 25 48.1 
Mehalla 51 39 76.5 22 43.1 
Kafr Zayat 38 29 76.3 15 39.5 
Zefta 55 23 41.8 9 16.4 
Samanoud 20 18 90.0 8 40.0 
Santa 43 27 62.8 16 37.2 
Kotoor 30 26 86.7 16 53.3 
Basyoon 28 23 82.1 8 28.6 
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Table 3.2.  Total age- and sex-adjusted incidence rates (per 100,000PY) for 
hepatocellular carcinoma (HCC) and squamous cell carcinoma of the bladder (SCC-B) by 
district.  Rates were standardized to the World Million.25  Chi-square analysis for both 
HCC and SCC-B showed significant variation across districts (P < 0.01).  
 
District HCC ASR SCC-B ASR 
Gharbiah Province 8.8 1.83 
  
Tanta 11.8 3.20 
El Mehalla El Kobra 6.8 2.97 
Kafr El-Zayat 9.8 0.65 
Zefta 5.9 0.38 
Samanoud 6.1 3.13 
Santa 8.9 4.07 
Kotoor 12.8 10.32 




Table 3.3.  HCC and SCC-B clusters identified by the Local Moran’s I statistic.  Spatial weights calculated for 9 nearest neighbors.  
All rates calculated as number of cases per 100,000PY. 
 
Cancer Type Cluster Risk No. Village ID Raw IR EB Smoothed IR Local Moran p-value 
























































































































































632 4.2 4.9 0.0557 0.0268






































































































































































Table 3.4.  HCC and SCC-B clusters identified by the scan statistic (Kulldorff method).  Scan thresholds: population included is no 
greater than 20% of the total provincial population, and the circle radius is no greater than 7km.  All rates calculated as number of 
cases per 100,000PY.  
 
Cancer Type Cluster Type No. Reported Cases Expected Cases Relative Risk # Villages p-value 

















































































































Figure 3.1.  Conceptual model showing the pathway by which schistosomiasis may 
effect hepatitis C virus infection and hepatocellular carcinoma via parenteral 
antischistosomiasis therapy during the antischistosomiasis campaign in Egypt (1950s – 
1980s). The relationship between infectious agents suggests sequelae (cancer) frequency 
could be measured as indicators of infection burden at the population level.  A greater 
burden of schistosomiasis infection would lead to more frequent exposure to PAT and, 





Figure 3.2.  Northern Egypt (Nile Delta), Gharbiah Province, and its eight districts.20 
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Figure 3.3. Raw and EB smoothed incidence rates (per 100,000PY) for HCC and SCC-
B. 3.3a: Raw HCC incidence rates; 3.3b: EB Smoothed HCC incidence rates; 3.3c: Raw 
SCC-B incidence rates; 3.3d: EB smoothed SCC-B incidence rates.  
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Figure 3.4. Clusters of HCC identified by the two methods. 3.4a: High-risk (dark) HCC 
clusters identified by the Local Moran test statistic; 3.4b: Low-risk (light) HCC clusters 
identified by the Local Moran test statistic; 3.4c: High-risk (dark) HCC clusters 
identified by the spatial scan test statistic; 3.4d: Low-risk (light) HCC clusters identified 





Figure 3.5. Clusters of SCC-B identified by the two methods. 3.5a: High-risk (dark) 
SCC-B clusters identified by the Local Moran test statistic; 3.5b: Low-risk (light) SCC-B 
clusters identified by the Local Moran test statistic; 3.5c: High-risk (dark) SCC-B clusters 
identified by the spatial scan test statistic; 3.5d: Low-risk (light) SCC-B clusters 





Figure 3.6. Clusters of HCC (circle) and SCC-B (triangle) identified by the two 
methods. 3.6a: High-risk (dark) clusters identified by the Local Moran test statistic; 3.6b: 
Low-risk (light) clusters identified by the Local Moran test statistic; 3.6c: High-risk 
(dark) clusters identified by the spatial scan test statistic; 3.6d: Low-risk (light) clusters 
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VIRAL HEPATITIS INFECTIONS IN HEPATOCELLULAR CARCINOMA 
CASES AND THE APPARENTLY HEALTHY POPULATION IN EGYPT:  





Hepatocellular carcinoma (HCC) comprises nearly 6% of all incident cancer cases 
worldwide, with the overwhelming majority occurring in the developing world.1 One of 
the least curable malignancies, HCC is the third most frequent cause of cancer mortality 
among men worldwide.1 Chronic infection with hepatitis B virus (HBV) and hepatitis C 
virus (HCV) have been cited as, by far, the most important etiologic agents.2  According 
to the World Health Organisation (WHO), approximately 350 million people are 
chronically infected with HBV and 170 million are infected with HCV.3-4  The relative 
importance of HBV and HCV as causative agents can vary greatly from region to region 
and over time.1,5  Selecting appropriate HCC prevention and control methods, therefore, 
depends on understanding the dynamics of these agents in a specified geographic region. 
Hepatocellular carcinoma in Egypt is currently undergoing a temporal shift in the relative 
importance of HBV and HCV as primary risk factors.  Hepatocellular carcinoma is the 
second most frequent cause of cancer incidence and mortality among men in Egypt.6  
Hospital-based studies from Egypt have reported an increase in the relative requency of 
all liver-related cancers in Egypt (>95% as HCC), from approximately 4.0% in 1993 to 
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7.3% in 2003.7-9   The Middle East Cancer Consortium recently reported that the 
incidence rate among males was seven times greater than the next highest rate (among 
Israeli Jews) and more than three times that reported in the United States Surveillance 
Epidemiology and End Results (SEER) summary.6  To explain this trend it is necessary 
to understand the dynamics of HBV and HCV in Egypt. 
Prior to implementing the HBV vaccine in the 1980s, chronic infection with HBV 
was widespread and considered the dominant etiologic factor in HCC development.10  
Childhood HBV immunization in Egypt today is estimated at 95% to 100%, thus making 
it likely that HBV-related HCC will steadily decline over the next few decades.11-12  
Unfortunately this major public health achievement has been eclipsed by the rise of the 
HCV epidemic, largely attributed to the mass parenteral anti-schistosomal therapy (PAT) 
and other iatrogenic exposures.13-16   Egypt is now plagued by the highest prevalence of 
HCV in the world, with estimates ranging from 6 to 28% and a reported average of 
approximately 13.8%.17-18  Recent investigations in Egypt have also shown the increasing 
importance of HCV infection in the etiology of HCC, now estimated to account for 40 to 
50% of cases.7-9  Just as many people were infected with HBV as with HCV during the 
PAT campaign; however, HBV only caused chronic infections in 5% or less of infected 
individuals, whereas chronic HCV infection developed in 70% to 80%.14,16  This has to 
do with the natural history of HBV, where the probability of developing chronic infection 
decreases with age.5,10  Since most individuals receiving PAT were older than 10-15 
years, they were at less risk for developing persistent HBV infection.16 
The future of HCC in Egypt and the magnitude of its socio-economic burden will 
be a legacy of the country’s unique HCV epidemic and the shifting dynamics of HBV 
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and HCV.  To date, there has been no systematic review of the literature to synthesize the 
results of published prevalence studies, including patterns over time.  There is, therefore, 
a need to calculate the fluctuating prevalences of HBV and HCV in Egypt over the past 2 
decades among a healthy population-based sample; there is also a need to synthesize data 
about  HCC patients, using appropriate meta-analytic tools.  This paper aims to calculate 
weighted average prevalences of HBV and HCV among two groups in Egypt from 1985 




Literature Search Methods.  MEDLINE , ISI Web of Science, ScienceDirect, 
and WHO regional indexed databases were used to search for articles published from 1 
January 1980 to 31 October 2007, by means of the MeSH terms: ‘hepatocellular 
carcinoma and Egypt’, ‘hepatitis B virus and Egypt’ and ‘hepatitis C virus or hepacvirus 
and Egypt’.  No language limitation was imposed. For HCC studies, the time and place of 
subject recruitment were cross-checked to avoid inclusion of the same cases in multiple 
articles.  Articles or reports from non-peer-reviewed sources were not considered for this 
analysis. 
Data Analyzed.  The key information abstracted from each study included:  
(1) Year(s) conducted (to account for the delay between field work and  
publication) 
(2) Sample size 
(3) Age range of participants (participants 18 years or older were considered  
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adults) 
(4) Geographic region of the sample population  
a. Upper or Lower Egypt 
(5) Type of residence 
 a. Urban or rural  
(6) Prevalence of HBsAg 
(7) Prevalence of anti-HCV  
(8) Generation of HCV serology test used 
Unfortunately, we did not examine sex differences in HBV and HCV prevalence, because 
too few of the studies reported marker prevalence stratified by participant gender. 
Inclusion & Exclusion Criteria.  Healthy population-based studies included the 
following sample populations: voluntary blood donors (VBD), replacement donors 
(RBD) (blood donated to replace blood consumed by specific patients, typically from 
friends or blood relations), healthy antenatal women, and community studies. We 
excluded studies from the following special groups who were assumed to be at special 
high risk: patients from sexually-transmitted-disease clinics, thalassemia clinics, 
hospitalised patients, professional or paid blood donors, sex workers, drug abusers, 
dialysis patients, and health care workers.  Healthy population-based studies with fewer 
than 100 participants were excluded from this analysis.  
HCC studies were limited to those examining incident cases to avoid temporal 
ambiguity and the possibility that virus infection may have occurred subsequent to the 
cancer diagnosis.  HCC studies with fewer than 25 participants were excluded from this 
analysis. 
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Eligible studies had to report prevalence of hepatitis B surface antigen (HBsAg) 
and/or antibodies against HCV (anti-HCV).  Studies were excluded if they failed to 
indicate the type of test used to assess infection status and if the sensitivity and specificity 
of the test was unknown.  Information regarding HBV infection and immunity status can 
be obtained from four common seromarkers: hepatitis B surface antigen (HBsAg), 
hepatitis B surface antibody (anti-HBs), total hepatitis B core antibody (anti-HBc), and 
IgM antibody to hepatitis B core antigen (IgM anti-HBc).  Of these markers, only HBsAg 
can identify current infection.  A positive result indicates either active or chronic 
infection.  Antibody markers cannot distinguish between naturally-acquired immunity 
and vaccine-related immunity.19  Since we wanted to measure the prevalence of naturally 
acquired infection, HBsAg was the seromarker of interest.  In addition, these tests have 
been available for a long time. They are inexpensive, simple to conduct and reliable, 
allowing them to be fairly standard even in low-resource settings.19  
 HCV infection status can be determined in two primary ways: enzyme 
immunoassay (EIA) or polymerase chain reaction (PCR).  EIA techniques indicate the 
presence of antibody (anti-HCV) while PCR can serve to confirm infection as well as 
measure viral load.  Both methods are markers of ongoing infection and do not correlate 
well with resolved infection.  As with HBsAg, anti-HCV does not distinguish between 
acute and chronic infection.20  While PCR techniques tend to be more accurate, they are 
far more expensive and, thus, infeasible for low-resource settings or areas with higher 
prevalence.  With a sensitivity greater than 95% and the availability of standardized test 
kits, the World Health Organisation (WHO) recommends EIA as the primary screening 
tool, and suggests PCR be used for clinical and case management purposes.20  For these 
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reasons, it is rare to find PCR tests reported in the literature from low-resource settings 
such as Egypt, and we believe the results of EIA are sufficiently consistent and reliable to 
be used in this analysis.  Though some studies did report both anti-HCV and PCR results, 
we only examined anti-HCV to limit bias due to varying test sensitivity and specificity.   
In addition, studies known or likely to have used first-generation ELISA for 
measuring anti-HCV were not included in the meta-analysis due to known problems of 
sensitivity and specificity of those assays.21  To date, there have been three generations of 
anti-HCV EIAs, with the first developed in 1990.  It suffered from poor sensitivity and 
could not detect antibody prior to 4 to 6 months following initial infection.  Second and 
third generation tests have dramatically improved sensitivity (>95%) and narrowed the 
window period between infection and anti-HCV detection.20  Consequently, this paper 
only considers studies that used second or third generation anti-HCV EIAs.  Only 3 
studies were excluded based solely on the generation of anti-HCV test used.  
We also applied specific definitions when classifying Lower and Upper Egypt as 
well as urban and rural settings.  Figure 4.1 identifies the locations of Upper and Lower 
Egypt.22  Generally speaking, Lower Egypt is in the north (designated as “Lower” 
because it lies downstream on the Nile) and Upper Egypt is in the south.  It has been 
hypothesized that prevalence of HCV infection varies between Lower and Upper Egypt 
(i.e. north and south).7-8  To examine this, we focused on studies of these two regions.  
Though Upper and Lower Egypt do not account for the entire population, they do contain 
the vast majority.  Other areas were a priori excluded as the literature is sparse, and we 
did not want to introduce bias based on differing regional health behaviors, etc.  After 
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completing the literature search, no studies were excluded solely on the basis of 
governorate. 
The Egyptian government classifies governorates as either fully urban or joint 
urban and rural.22  The official distinction between urban and rural is reflected in the 
lower tiers.  Fully urban governorates have no districts (markazes).  The district is 
specifically defined as a conglomeration of villages around a capital city. In joint urban 
and rural governorates, therefore, urban locations are comprised of each district’s capital 
city.  All other locations in that governorate are considered rural.  Some urban 
governorates consist of just one city which is divided into smaller urban neighborhoods.  
For example, the governorate of Cairo consists of 23 urban neighborhoods.  Since a 
disparity in HCV prevalence between urban and rural populations has been observed, we 
wanted to test the hypothesis systematically, using strict and consistent definitions.13-16,23  
We followed this classification scheme in our designation of urban and rural study 
settings. 
Power Concerns.  We noted difficulties with statistical power could be 
encountered at two levels: small participant sample size in individual studies as well as 
small sample size of studies, particularly when stratified by sub-factors of analysis (e.g. 
geographic region, age group, etc).  Pooling 30 studies with sample sizes of 50, for 
example, may not be as reliable as pooling 5 studies of 300 participants.  Nevertheless, it 
is difficult to compare multiple studies of a particular geographic region to a single study 
in a different region, regardless of sample size.  Since little is available on power 
calculations for these biomarkers in Egypt, we opted to take a more qualitative approach.  
Egypt does experience a higher burden of HBV and HCV in its apparently healthy 
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population as compared to other countries, and it is well known that an overwhelming 
majority of its HCC cases test positive for HBV and/or HCV.  Therefore, we were 
comfortable setting the lower limit of sample size for healthy population samples at 100 
and for HCC cases at 25.  This resulted in the exclusion of 2 healthy population studies 
and 3 HCC studies based solely on the sample size requirement. 
Meta-Analysis.  Data were analyzed according to three different categories: HBV 
prevalence among healthy population-based samples, HCV prevalence among healthy 
population-based samples, and HBV and HCV prevalence among incident HCC cases.     
Summary prevalence measures were calculated as weighted averages, using a 
standard method.25  The individual prevalence rate for each study was multiplied by the 
corresponding sample size and divided by the total (pooled) sample size of all studies. 
These summary measures were used to compare differences between sub-groups in 
aggregate as well as over time.  Chi-square tests were performed to determine significant 
differences in prevalence with respect to age category (child vs. adult), geographic 
location (Upper vs. Lower Egypt),  type of residence (urban vs. rural), and study period 
(time; treated as a continuous variable), using α = 0.05 as the significance cut-off.  We 
used linear regression models to examine risk factors in combination, with either HBV or 
HCV prevalence as the dependent variable.  The four risk factors mentioned above were 
all considered for the healthy population studies.  Time was the only predictor examined 
for HBV or HCV among HCC cases.  Prevalence was log transformed to obtain a normal 
distribution, and the models were weighted by study sample size.   
All manipulations and analyses were performed using SAS v 9.1.3 (SAS Institute 




Literature Search Results.  The initial search generated over 1500 potential 
articles.  After refining the list to relevant articles, we identified a total of 200 unique 
articles: 107 from MEDLINE, 57 from WHO regional indexed databases, 34 from ISI 
Web of Science, and 2 from ScienceDirect.  A hand search of the reference lists of 
selected articles identified a few additional relevant studies.  Final results from our search 
yielded a total of 39 unique peer-reviewed studies meeting our inclusion/exclusion 
criteria (Appendix 4.1). Several studies measured both HBsAg and anti-HCV, and some 
of them also involved more than one study site, providing prevalence measures for 
multiple population samples.  Of these studies, 25 studied healthy population-based 
samples, and 14 were specific to HCC cases.  The healthy population-based studies 
included 12 with HBsAg measurements and a total sample size of 7,597, and 24 with 
anti-HCV measurements and a total sample size of 42,457.  The 14 HCC studies with 
HBsAg and/or anti-HCV information had a total case population of 3,275.  Data for HBV 
among healthy population-based samples covered the time period 1983-2002, HCV 
studies healthy population-based samples spanned the time period 1991-2004, and HCC 
studies ranged from 1985-2005.  Study details are presented in Tables 4.1-4.2.  Chi-
square test results for all categories among HBV, HCV and HCC are presented in Table 
4.3. 
HBsAg among the healthy population-based samples.  Table 4.4 presents the 
major findings from examining the prevalence of HBsAg among healthy population-
based samples.  Overall, the prevalence was 6.7% (±1.4%), with no significant variation 
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over time (P = 0.59).  When the studies were separated according to age, we found a 
similar pattern.  Results showed a significant difference between prevalence among 
adults and children (P < 0.0001).  Adults averaged a prevalence of 8.0% (±1.7%), with 
children averaging at 1.6% (±0.3%), likely a function of the introduction of the HBV 
vaccine (Figure 4.2).  
Eleven of the 12 studies provided information regarding individuals from Upper 
or Lower Egypt.  Only one study examined Upper Egypt, while the remaining 11 
examined Lower Egypt.  A summary measure of the Lower Egypt studies revealed a 
prevalence of 4.6% (±1.3%), much lower compared to that of the Upper Egypt study 
(11.7%), which was statistically significant (P < 0.0001).  Since we only have one study 
from Upper Egypt, it is difficult to know how representative it is, but it should be 
mentioned that it was a community-based sample of 1064 individuals. 
Anti-HCV among healthy population-based samples.  Table 4.4 presents the 
major findings from examining the prevalence of anti-HCV among healthy population-
based samples.  Overall, from 1990-2004 the prevalence was 13.9% (±1.6%).  It was 
significantly higher among adults (15.7±1.8%) versus children (4.0±2.1%; P < 0.0001).  
Unlike our findings with HBsAg, the prevalence of anti-HCV did appear to vary over 
time, both in summary and by age group (Figure 4.3; Table 4.3).  Studies from 1990-
1994 showed a higher prevalence of 21.8 (±3.3%) when compared to the time periods 
1995-1999 (12.5±3.4%) and 2000-2004 (13.5±2.0%), which were not statistically 
different from one another.  This trend continued for adults (P < 0.0001), but child 
studies suggested a continuing decline in prevalence (P < 0.0001; Figure 4.3). 
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Analysis of anti-HCV by geographic region found the reverse trend from what 
was observed with HBsAg (Figure 4.4).  Of the 24 total studies, 19 had specific 
information on Lower Egypt, and 2 had specific measurements for Upper Egypt.  Studies 
from Lower Egypt showed a higher prevalence (15.8±1.8%) than those from Upper 
Egypt (6.7±2.9%), which was significant (P < 0.0001).  This pattern remained highly 
significant after stratifying by age group (Table 4.3). 
We were also able to examine urban versus rural populations (Figure 4.5).  We 
found 10 studies examining specifically rural groups and 3 that looked at urban 
populations.  As has been suggested in the literature, we found a significantly higher 
prevalence of anti-HCV among rural individuals (13.4±2.3%) compared to urban 
individuals (5.5±2.0%; P < 0.0001).  Again, we found this trend to be highly significant 
after stratifying by age group (Table 4.3). 
HBsAg and anti-HCV among HCC cases.  Table 4.4 presents our findings from 
examining the prevalence of HBsAg and anti-HCV among HCC cases.  There were 12 
studies with HBsAg data covering the time period 1985-2004, and 11 studies with anti-
HCV measurements spanning 1991-2004.  The overall prevalence of HBsAg was 25.9% 
(±4.7%), and that of anti-HCV was 78.5% (±3.6%), and this difference was statistically 
significant (P < 0.0001).  Both markers showed highly significant changes over time, 
with HBsAg decreasing (1985-1996: 32.7±5.2%; 1997-2004: 21.9±8.9%; P < 0.0001), 
and anti-HCV increasing (1991-1996: 68.5±6.6%; 1997-2004: 85.9±2.6%; P < 0.0001) 
over time (Figure 4.6a). 
Of the HCC studies included, 9 (N = 1711) reported both HBsAg and anti-HCV 
measurements.  We repeated the above analysis for just these 9 studies to reduce the 
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possibility of bias, and we found similar results.  The overall prevalence of HBsAg was 
24.5% (±5.1%), and that of anti-HCV was 84.1% (±2.4%).  The decrease in HBsAg 
remained significant (1991-1996: 30.0±5.3%; 1997-2004: 21.9±8.9%; P = 0.001).  A 
slight increase in anti-HCV prevalence was observed for the revised group of studies, but 
it was no longer significant (1991-1996: 80.3±4.3%; 1997-2004: 85.9±2.6%; P = 0.2015) 
(Figure 4.6b). 
Linear Regression.  Final models from the regression analysis are presented in 
Table 4.5.  Among the healthy population studies, age was highly significant as a sole 
predictor, but it lost significance in the presence of study year suggesting that these are 
not independent predictors for either HBV or HCV prevalence (not shown).  Type of 
residence (urban vs. rural) was not available for the HBV studies, so our final model only 
examines study year and geographic region (Upper vs. Lower Egypt).  Our final model 
included study year (P = 0.03), region (P = 0.15), and an interaction term for year and 
region (P = 0.06), suggesting that HBV prevalence has generally decreased over time but 
has also changed geographically over time.  The final model for HCV prevalence 
included study year (P = 0.08), region (P = 0.004), residence (P = 0.17), and a 3-way 
interaction term for year, region, and residence (P = 0.03), suggesting more complex 
shifts in prevalence patterns with respect to space (region and residence) and time. 
The regression models used to examine HBV and HCV among HCC cases 
produced results consistent with what we would expect from the chi-square analysis.  
Study year was significantly associated with HBV, indicating decreasing prevalence over 
time, but it was not associated with HCV.  It is possible that HCV among cancer cases 
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This is the first systematic review and meta-analysis of hepatitis B and C virus 
prevalence in Egypt and should provide some insight for understanding the dynamics of 
liver disease in Egypt and how best to address the problem.  For both viruses among 
healthy population-based samples, we found adults had a significantly higher prevalence 
than children, supporting a cohort effect.  For HBV, it seems likely that the cohort effect 
would be related to the introduction of the hepatitis B vaccine in 1992, which was 
incorporated into the Expanded Programme on Immunisation, and is only given to 
children, leaving adults at the time of program implementation unvaccinated.  The cohort 
effect seen in HCV is likely related to the early association between the parenteral 
antischistosomiasis therapy (PAT) campaign and HCV transmission.  Oral therapies for 
schistosomiasis were gradually adopted in the 1980’s, dramatically reducing 
transmission.14,26  It is still unclear, however, what the rate of HCV transmission is 
presently, in the absence of the original primary route.  Since several of the childhood 
HCV studies were late enough that none of the children would have been exposed to the 
PAT campaign, it does appear that HCV has continued to be transmitted.  It will be 
important to understand the emerging routes and rates of transmission to effectively 
control the burden of liver disease in Egypt. 
Our analysis confirmed reports of large scale geographic heterogeneity in HCV 
prevalence.7-8  We did find prevalence to be significantly higher in Lower Egypt as 
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opposed to Upper Egypt, which in turn supports the hypothesis of PAT as the dominant 
force driving the HCV epidemic.  Individuals living in Lower Egypt experienced a 
greater burden of schistosomiasis, and therefore a greater level exposure to PAT.7-8  This 
is in contrast to what we saw with HBV, which appeared to be higher in Upper Egypt 
versus Lower Egypt.  Unfortunately, we did not have access to multiple studies of HBV 
prevalence in Upper Egypt, so it is best not to draw too many conclusions from that 
analysis. 
We were also able to examine the relationship of HCV with urban and rural 
populations.  We were able to support the hypothesis that HCV prevalence is higher 
among rural residents than urban residents.13,23  This is also in line with the PAT 
hypothesis; that rural residents would have a greater burden of schistosomiasis, and 
therefore greater exposure to PAT. 13,23  Unfortunately, we were unable to find this type 
of disaggregated data for HBV for comparison, and since most of the HCC studies were 
hospital-based, it is difficult to speculate on future effects, though it would be expected 
that more HCC cases would be found in rural regions.  This is contrary to a recent 
population-based HCC study from Lower Egypt that found cases to be nearly twice as 
likely to come from urban versus rural areas.27  Due to the significant lag time between 
viral infection and development of HCC, it is possible Egypt is witnessing the end of a 
cohort of higher urban exposure that will soon transition to a population dominated by 
rural exposure.   
Finally, it was illuminating to examine the trends in HBV and HCV prevalence 
over the past 20 years.  As was expected to some degree, HBV prevalence was relatively 
low overall, but has experienced a slight decrease over the time period included here, 
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probably due to the implementation of earlier control measures followed by the vaccine.  
Infection levels in children suggest that this infection may soon be an insignificant 
element of the liver disease burden in Egypt.  Prevalence of HCV, however, showed 
greater variance over time.  Among both children and adults there was a general decline 
in prevalence over time, with adults stabilizing at just below 15%, and children 
continuing to drop to nearly 1% by the period 2000-2004.  Regression analyses found 
significant time interactions for both HBV and HCV, suggesting a more complicated shift 
in prevalence patterns over time that includes geographic changes as well.  Detailed risk 
factor data are needed to further characterize these interactions and distinguish between 
the effects of population migration, changing risk factor patterns, etc. It would also be 
valuable to match these prevalence figures with incidence studies to reconstruct the 
different epidemic curves, shedding light on viral dynamics and guiding predictions about 
future trends in infection. 
We felt it was important to gain a summary understanding of the status of HBV 
and HCV prevalence in healthy population-based samples, but that this should be 
complimented by an understanding of these viral dynamics among HCC cases as well.  
Frequently the burden of HBV and HCV cannot easily be quantified apart from its 
chronic sequelae.  By understanding the degree to which these viruses contribute to HCC, 
it is possible to see the impact they have on overall population health. 
We found the overall prevalence of HBV among HCC cases to be nearly 25%, 
and the prevalence of HCV infection to be as high as 84%.  We also noted some 
differences within infections over time, though they were not statistically significant, 
possibly a result of low power.  It appeared that HBV infection declined from a 
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prevalence of 30% between 1991-1996 to 22% between 1997-2004.  Conversely, HCV 
infection among HCC cases may have increased slightly over this same time period from 
80 to 86%.  This seems fitting when we consider the impact of different cohort effects.  
Current cancer cases represent individuals being exposed to these viruses 20-30 years 
prior.  These cases may represent the individuals at the end of the pre-HBV vaccine 
period and the beginning of the PAT campaign.  Based on general population estimates, it 
seems likely that prevalence of HBV will continue to decline and HCV will continue to 
increase among HCC cases, at least for a while.  This has been supported by a projections 
from a mathematical model designed to predict the burden of HCV in Egypt over the next 
couple of decades.23  What will happen after that will depend largely on the new HCV 
incidence patterns in the absence of the PAT campaign, which remain to be quantified by 
future research. 
In addition to the lack of data regarding the geographic distribution of HBV and 
HCV prevalence, some limitations of this present review should be considered.  It is 
possible that despite our extensive literature search, the specific search terms used may 
not have captured all quality papers published in peer-reviewed indexed journals. To 
counter this problem, we supplemented our electronic search by a hand search of 
references from selected articles, but there is always the possibility that we missed some 
data.  
We attempted to gain representative samples of the Egyptian healthy population 
by accepting community-based samples, but we also included some large scale 
convenience samples such as healthy pregnant women attending clinics and voluntary 
blood donors.  John, et al have questioned the inclusion of voluntary blood donors in 
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systematic reviews.28 They refer to a study among voluntary donors at Vellore where the 
HBV carrier rate was 0.7%, which they suggest is artificially low because voluntary 
donors are a self-selected group and persons who are found to be positive do not come for 
repeat blood donation. They suggest using data from replacement donors. Batham, et al. 
conducted an analysis of different population groups tested in Delhi.29  On examining the 
forest plots from these studies, voluntary donors, replacement donors and ante-natal 
mothers all had prevalences close to the overall mean, suggesting it was appropriate that 
all these groups be included in systematic reviews.  
The extent to which the HCC cases we reported upon are representative is also 
unclear, since in most cases only hospital-based studies were available.  We did focus on 
cancer studies from the larger, nationally recognized cancer centers, which serve as 
diagnostic and treatment facilities for the overwhelming majority of cancer cases 
throughout Egypt. 
It is understood that only a large, national epidemiological study can provide a 
definitive answer regarding the overall prevalence of hepatitis B and C viruses in Egypt. 
In the absence of such a national sample survey, which would require a large 
mobilization of resources, a systematic review and meta-analysis of high quality studies 
previously conducted may provide the best compromise. 
 
Table 4.1. Data abstracted from studies examining the general population.  Numbers following author name correspond to the full 
citation in Appendix 4.1. VBD = Voluntary Blood Donors; HPW = Healthy Pregnant Women.  
 
Marker Author [Citation] Study Period Population Region Residence Age N Prevalence (%) 
HBsAg Sherif, et al [1] 
Sherif, et al [1] 
Gumie, et al [2] 
El-Sherbini, et al [3] 
El-Hawey, et al [4] 
Arthur, et al [5] 
Mabrouk, et al [6] 
Darwish, et al [7] 
Darwish, et al [8] 
El-Sherbini, et al [3] 
Reda, et al [9] 





































Urban & Rural 
Urban & Rural 
Urban & Rural 
Urban & Rural 
Rural 
Urban & Rural 
Urban & Rural 
Urban & Rural 
Urban & Rural 
Rural 











< 18 yr 
< 18 yr 

























Anti-HCV El-Sherbini, et al [10] 
El-Sherbini, et al [10] 
El-Sherbini, et al [10] 
Fathalla, et al [11] 
Arthur, et al [5] 
Darwish, et al [7] 
El-Sherbini, et al [10] 
Kumar, et al [12] 
Darwish, et al [8] 
Kassem, et al [13] 
Mohamed, et al [14] 
Mohamed, et al [14] 
Stoszek, et al [15] 
Abdel Aziz, et al [16] 
Nafeh, et al [17] 
Tanaka, et al [18] 
Rizk, et al [19] 
Bakr, et al [20] 
Mohamed, et al [21] 
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Urban & Rural 
Urban & Rural 
Rural 
Rural 
Urban & Rural 
Urban & Rural 
Urban & Rural 
Rural 
Rural 
Urban & Rural 
Rural 
Rural 
Urban & Rural 




< 18 yr 
< 18 yr 








< 18 yr 



















































Raouf, et al [23] 
El-Sadawy, et al [24] 
El-Sadawy, et al [24] 













Urban & Rural 
Rural 
Urban 














VBD = Voluntary Blood Donors; HPW = Healthy Pregnant Women. 
Total N for HBsAg studies = 7,597 






Table 4.2. Data abstracted from studies examining HCC cases.  All studies had a mean age between 45–60 yrs. 
 
Author Study Period Patient Source Study N HBsAg+ (%) Anti-HCV+ (%) 
Ahmed, et al [26] 
El-Soudani, et al [27] 
El-Sherif, et al [28] 
El-Zayadi, et al [29] 
Abdel-Wahab, et al [30] 
Abdel-Wahab, et al [31] 
Angelico, et al [32] 
Attia, et al [33] 
Hassan, et al [34] 
Mabrouk, et al [35] 
Yates, et al [36] 
El-Zayadi, et al [37] 
El-Kafrawy, et al [38] 
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National Cancer Institute – Cairo 
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Total N for all studies = 3275.   





Table 4.3. Prevalence and chi-square results for all categories of analysis among healthy populations and HCC cases. 
 
Population Category of Analysis Comparison Group Prevalence (%) N χ2  P-value 











































































































































































































































HCC Cases Infection Prevalence (Total) 
 
 
Infection Prevalence (1985-1996)* 
 
 
Infection Prevalence (1991-1996)** 
 
 
Infection Prevalence (1997-2004)* 
 
 
Infection Prevalence (1997-2004)** 
 
 
HBV Prevalence (1985-2004)* 
 
 
HBV Prevalence (1991-2004)** 
 
 















































































































*Analysis performed on all HCC studies 




Table 4.4. Prevalence and standard error of viral markers among healthy populations and HCC cases. 
 
Population Marker Category of Analysis Time Period or Location HBsAg+ (%) SE # Studies Total N 

















































































































































































































































































































































Table 4.5. Results from multivariate linear regression analyses. 
 
Population Prevalence (%) Model Predictors Parameter (SE) p-Value 

















































Figure 4.2. Prevalence of HBsAg+ individuals.  Pooled measurement is based on 12 
studies (N = 7,597) and spans 1983-2002.  Adult measurement is based on 8 studies (N = 
6,129) and spans 1983-1995.  Child measurement is based on 4 studies (N = 1,468) and 
























Figure 4.3. Prevalence of anti-HCV+ individuals over three time periods: 1990-1994, 
1995-1999, and 2000-2004.  Pooled measurement is based on 24 studies (N = 42,457).  
Adult measurement is based on 17 studies (N = 35,752).  Child measurement is based on 
7 studies (N = 6,705). The difference observed across time period was highly significant 





























Figure 4.4. Prevalence of anti-HCV+ individuals by geographic region: Lower Egypt and 
Upper Egypt.  Lower Egypt measurement is based on 19 studies (N = 27,118).  Upper 
Egypt measurement is based on 2 studies (N = 8,839).  Differences between Lower and 




















Figure 4.5. Prevalence of anti-HCV+ individuals by residence: rural or urban.  The rural 
measurement is based on 10 studies (N = 27,100).  The urban measurement is based on 3 





















Figure 4.6a. Prevalence of HBsAg and anti-HCV+ among HCC cases over two time 
periods: 1985-1996 and 1997-2004.  The HBsAg estimate for 1985-1996 is based on 8 
studies (N = 676).  The HBsAg estimate for 1997-2004 is based on 4 studies (N = 1,158).  
The anti-HCV estimate for the first period actually spans 1991-1996 and is based on 6 
studies (N = 982).  The anti-HCV estimate for 1997-2004 is based on 4 studies (N = 
1,158).  Differences across biomarkers as well as within biomarkers over time were 

























Figure 4.6b. Prevalence of HBsAg and anti-HCV+ among HCC cases over two time 
periods: 1991-1996 and 1997-2004, using only studies that reported both HBsAg and 
anti-HCV measurements.  The estimates for 1991-1996 are based on 5 studies (N = 553).  
The estimates for 1997-2004 are based on 4 studies (N = 1,158).  Differences between 
HBsAg and anti-HCV were significant (P < 0.0001), as were differences within HBsAg 
prevalence over time (P = 0.001) but time differences within anti-HCV were not 
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THE HEPATITIS C VIRUS EPIDEMIC IN EGYPT: ESTIMATING PAST 




 Hepatitis C virus (HCV) infection is gaining increasing attention as a global 
health problem, with approximately 3% of the world’s population infected.1-2  These 
individuals are at greater risk for developing cirrhosis and/or hepatocellular carcinoma 
(HCC).  Egypt reports the highest prevalence of HCV worldwide, ranging from 6 to more 
than 40% with an average of 13.8%.3-5  In populations of blood transfusion recipients 
over the age of 30, this rate has been reported to be as high as 73%, and in the general 
population aged 40-60 years this rate can be as high as 55%.  At the same time, the rate in 
children is much lower, ranging between 2-10%.3-5  While the rate in children is much 
lower than that in the older population, it is still considered high by World Health 
Organization (WHO) standards, where rates greater than about 4% are considered high.2 
 In Egypt, the major route of exposure to HCV appears to be the mass parenteral 
antischistosomal treatment (PAT), with more than 35 million injections given over a 20-
year period (1960–1980).3  Despite termination of this program and the implementation 
of measures designed to reduce hospital-related infection, HCV transmission continues. 
 Because the prevalence of HCV is so much higher than that of HBV infection, the 
attributable fraction of HCV (60%-70%) and the anti-HCV rate (75%-90%) has become 
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the leading risk factor for HCC in Egypt.6  Research has indicated an increase in the 
relative frequency of all liver-related cancers in Egypt (>95% as HCC), from 
approximately 4.0% in 1993 to 7.3% in 2003.7  Now the second highest cause of cancer 
incidence and mortality among men, HCC in Egypt occurs at rates significantly greater 
than those seen in surrounding Middle Eastern countries as well as the United States.8 
 Incidence data are limited, however, because researchers have been plagued by 
logistical and methodological difficulties.  Initial infection is rarely symptomatic, and 
chronic carriage is insidious.  Nevertheless, it is essential to characterize the HCV 
situation in Egypt in order to predict the future health burden and guide appropriate 
health policy to confront the issue. 
 Mathematical techniques provide a practical approach for making reasonable 
estimates about the history of the HCV epidemic and future predictions of HCV-related 
morbidity and mortality.  Methods for indirectly calculating age-specific incidence using 
sero-prevalence data were developed throughout the 1980’s.9-11  Saidel et al (1996) 
successfully validated one of these methods for HIV by comparing its predictions with 
observations from an incidence study.12  Such a method is advantageous, as it uses data 
from a single cross-sectional survey to estimate incidence, and is particularly appropriate 
for developing countries where incidence data are frequently unavailable or unreliable.  
The purpose of this study was to indirectly estimate the past incidence of HCV 
infections in Egypt using sero-prevalence data and estimate future HCV-related 





 Prevalence and population data.  Age-sex-specific population and mortality 
data for five-year age groups were obtained from Egypt’s Central Agency for Public 
Mobilization and Statistics (CAPMAS) and the World Health Organization (WHO).13-14 
 Prior systematic review of the literature identified high quality HCV prevalence 
studies for the period 1992-2005.  A detailed description of these studies and their 
methods are presented in Chapter 4.  We selected five studies from the period 2001-2002, 
which we considered to have the greatest amount of detail and the highest 
methodological quality (Table 5.2).4,15-18  All studies were conducted on apparently 
healthy community-based populations.  Third generation ELISA was used in all cases to 
test for HCV antibody.  These studies covered ages 5-60+ years as well as geographic 
regions of interest (Upper and Lower Egypt; see Chapter 4 for detailed discussion).  
Since it is known that prevalence varies significantly between children and adults as well 
as between Upper and Lower Egypt, this sample of studies is highly representative of 
Egypt when considered in aggregate. 
Age-specific prevalences across studies were compared using the chi-square test 
to determine if pooling results would be appropriate.  No significant differences were 
found among adults from Lower Egypt, children from Lower Egypt, adults from Upper 
Egypt, or children from Upper Egypt.  Summary age-specific prevalence measures as 
well as male:female ratios from these studies were calculated as weighted averages, using 
a standard method.19  The individual prevalence rate for each study was multiplied by the 
corresponding sample size and divided by the total (pooled) sample size of all studies. To 
populate the initial values of the HCV Infection health state in the Markov model, these 
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summary age-specific prevalence proportions (adjusted for sex) were multiplied by their 
respective census population values.  
 Incidence estimates.  The method for estimating age-specific incidence from 
prevalence data was originally described by Leske (1981), Podgor (1983), and Podgor 
and Leske (1986).9-11  Though initially developed for studying glaucoma, Laidel (1996) 
tested model predictions against observed incidence for HIV/AIDS and determined the 
model can provide crude estimates of one-year age-specific incidence rates that are 
similar to those observed in longitudinal studies of HIV/AIDS.12  For these calculations, 
we chose to select only one of the studies mentioned above, so as not to introduce bias.  
Since we are inferring incidence measures, it is best not to pool studies where HCV sero-
prevalence was measured by different researchers on different populations.  We chose to 
focus our investigation of incidence on the data from Arafa, et al (2005), which presents 
age-specific prevalence from an area in Lower Egypt, the region known to have higher 
levels of HCV in Egypt.6,17 
 Incidence is derived by using estimated prevalence of disease at the beginning and 
end of an age interval and the known age-specific mortality rates during the interval. The 
model is based on the functional relation between a risk (CI) and a rate (ID) that:  
CI = l - e - ( I D X Δt ) 
Where ID is incidence density, CI is cumulative incidence, and Δt is the elapsed time 
(which could be defined by age differences), as long as the assumption of constant 
incidence within a time interval is not violated.12  After accounting for age-specific 
mortality within age intervals, Leske (1981) proposes the following:9 
            ln(1-Πx)                (1 – (1 – Πx)(1 – qx) 
  Ix =     --------------------------     x --------------------------- 




Ix = Incidence rate for the age interval 
 
Px = Prevalence proportion at the beginning of the interval 
 
qx = Probability of dying during the age interval 
 
x+1 = Age interval immediately following x 
 
 Px+1 - Px 
Πx =   ------------- 
    1 - Px 
 
 After solving for Ix, it is divided by the number of years in the age interval to 
estimate the mean annual rate for time interval x.  In 1983, Podgor validated this model 
against other, more established methods.10  For more details on the derivation and 
validation of this method, see Leske (1981), Podgor (1983), Podgor and Leske (1986), 
and Saidel (1996).9-12  Variance and standard error for model estimates were calculated 
using the “delta method” described by Armitage (1971) and Leske (1981):9,20 
Var (Ix) = [∂Ix/∂Πx]2  Var (Πx) 
 In order to use this model, it is necessary to address its assumptions.9-10,12  First, 
we assume that infection is lifelong and irreversible.  We limit our analysis to chronically 
infected individuals, as the rate of remission is quite low. In addition, treatment for HCV 
in Egypt is limited and rarely successful in treating infection.  The second assumption is 
that mortality rates are constant throughout the interval of analysis.  By limiting age 
intervals to 5- or 10-year periods, it is reasonable to assume little fluctuation in mean 
mortality rates.  In sensitivity analyses, we found the estimates to be fairly stable in the 
presence of varying mortality rates.  The final assumption states that disease incidence 
and population composition with respect to risk factors for disease are constant during the 
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interval of analysis.  Since the prevalence of HCV is high, it is possible that the 
composition of risk groups may change over time.  Nevertheless, by restricting our age 
intervals to 5- or 10-year periods, we are limiting the degree to which we violate the 
constancy assumption.  Unfortunately, the model estimates are not robust when one age 
interval is followed by an interval with lower prevalence (results in a negative incidence).  
For the purpose of this analysis, we excluded estimates under those conditions. 
 Future HCV-related morbidity/mortality.  We used a Markov simulation 
model to predict HCV-related morbidity and mortality among a cohort representative of 
the HCV-infected population in Egypt (Figure 5.1).  Cohort members move among health 
states over 1-year time steps for 20 years.  By tracking the proportion of the cohort 
developing sequelae, we are able to estimate the future health burden.  The likelihood of 
health state transitions was based on probabilities derived from a review of the literature 
as well as publications from the WHO Hepatitis C Working Group (Table 5.1) [Appendix 
5.1].  Based on error estimates reported in the literature and cited by the WHO Hepatitis 
C Working Group, we performed sensitivity analysis on four of the transition parameters.  
The upper and lower bounds used in that analysis are presented in Table 5.1. 
 The model is set up to include ages 0 to 80 (time step = 1 year). Anyone alive at 
age 80 years dies by age 81. Since life expectancy in Egypt is 69 for males and 73 for 
females, and the population over 80 years accounts for only 0.3% of the total population, 
we found this age structure to be reasonable.14 In order to incorporate aging into the 
model, we added the probability of remaining in a health state from one time step to the 
next, which is simply [1 – sum(transition probabilities to different health states)]. This 
exists for all health states except the original HCV Infection. No one remains in the HCV 
 
 128
infection health state after the first time step, when people are either moved to chronic 
infection, or removed from the system in the resolution health state. 
 Age-sex-specific background mortality rates were obtained from the WHO and 
are applied to the following health states: chronic HCV infection, compensated cirrhosis, 
and decompensated cirrhosis.14  All deaths from hepatocellular carcinoma are considered 
to be attributed to it. No deaths occur in the first time step. Typically, hepatitis C 
infection resolves or becomes chronic within the first year of infection.1-2 Since our 
prevalence estimates are population-based, the first time step is designed to appropriately 
calculate the number of chronically infected individuals. 
 Sex is incorporated only insofar as generating the initial population structure and 
applying age-sex-specific background mortality.  Though we hypothesize that transition 
probabilities may indeed be different by sex, they have yet to be clearly defined in the 
literature and from prospective cohort studies.  Since previous research has indicated a 
greater proportion of males are infected in Egypt versus females (Chapter 4), sex is 
included to reflect these different initial values.  For the Markov model alone, it provides 
little beyond the initial values and the ability to project sex-specific health outcomes. 
 We estimated the burden related to disability or mortality from hepatitis C. We 
used the computer simulation to determine the years of life spent by the cohort with 
decompensated cirrhosis or hepatocellular carcinoma. To estimate the years of life lost, 
we also compared life expectancy estimates for the chronic hepatitis C population with 
those for an age- and sex-matched general population. These estimates calculated 
premature mortality and assumed permanent disability once patients developed 
decompensated cirrhosis or hepatocellular carcinoma but did not consider quality-of-life 
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deficits, as no such studies have been reported from Egypt that would provide appropriate 
quality of life information for HCV infection. 
We chose not to extend the model beyond 20 years for two reasons: 1) the natural 
history beyond 20 years is less certain weakening our confidence in parameter estimates; 
and 2) estimates of disease and death are less meaningful as they would not include 
incident cases who became infected during the period of analysis (due to the 
unavailability of incidence data). 
 
RESULTS 
 Age-specific prevalence.  All studies used in calculating summary measures had 
sample sizes greater than 1400, reducing the probability of bias in prevalence estimates 
due to low power (Table 5.2).  Chi-square tests revealed no significant differences 
between studies measuring redundant populations (i.e. adults from Lower Egypt), so we 
proceeded with calculating summary measures for the natural history model (not shown). 
Summary prevalence estimates were calculated for the following age groups: 5-9, 
10-14, 15-19, 20-29, 30-39, 40-49, and 50+.  As expected, prevalence consistently 
increases with age except for a decrease between the age groups 40-49 and 50+.  The 
decrease in the final age group could be related to lower exposure to the anti-
schistosomiasis therapy so tightly linked to HCV infection.  Pooled estimates also 
revealed a male:female ratio of 1.2 for ages 0-19 years and 1.6 for individuals 20 years or 
older. 
Incidence estimates.    Raw prevalence measures used in the calculation of 
incidence (from Arafa et al, 2005) were smoothed by fitting them to a logistic curve (1 / 
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e(-a-bx)), where a = -4.172 and b = -0.076 (Figure 5.2).  Table 5.3 presents the results from 
the age-specific incidence calculations.  Mean annual incidence rates were obtained by 
dividing the model estimate by the number of years included in the age interval (5 years).  
Model estimates ranged from 2.01 to 25.47 per 1,000 person-years.  The highest 
incidence rates were calculated for those 35 years and older.  Such high incidence for 
those 35 years and older is consistent with the age cohort effect seen with respect to the 
PAT campaign.  We were unable to estimate the incidence for those older than 50 years, 
because the prevalence significantly decreases beginning with the 55-59 year age group.  
This particular method for estimating incidence loses accuracy under these conditions 
and frequently results in the calculation of a negative incidence rate.  
 Future HCV-related morbidity and mortality.  Table 5.4 presents the major 
predictions from the Markov model estimating future HCV-related morbidity and 
mortality in Egypt.  Upper and lower bound estimates from the sensitivity analysis are 
also included.  Based on review of the prevalence studies, approximately 8.84 million 
individuals (4.98 million males and 3.86 million females) are estimated to be infected 
with HCV in Egypt, resulting in 6.62 million with chronic infection.  Our model 
predicted this cohort would yield a total of 127,821 deaths due to decompensated 
cirrhosis and 117,556 deaths due to hepatocellular carcinoma over the next 20 years.  The 
highest proportion of deaths related to HCV will occur 10-20 years from now.  Deaths 
due to HCC appear to peak within 15-16 years, whereas deaths due to decompensated 
cirrhosis only begin to flatten out in the final two years of analysis (Figure 5.3).  Deaths 
from HCC are greater than deaths from decompensated cirrhosis earlier in the model, due 
to the fact that individuals diagnosed with HCC in Egypt typically do not live past one or 
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two years, whereas an individual with decompensated cirrhosis can live several years 
before succumbing to the condition. 
 In addition to the 244,377 HCV-related deaths predicted by the model, when 
compared with an age-matched general population over the same time period, the HCV-
infected cohort would have accumulated 3,862,643 years of compensated cirrhosis, 
750,210 years of decompensated cirrhosis, 132,894 years of hepatocellular carcinoma, 
and the loss of 32.86 million years of life. 
 
DISCUSSION 
 The objective of this study was to estimate past incidence of HCV using an 
indirect method and make projections about the future health burden using a natural 
history model.  Despite Egypt’s status as the country with the highest levels of hepatitis C 
virus in the world, few studies have been done to characterize the dynamics of 
transmission, how they may have changed over time, and what this means for the future 
of health in Egypt.  There is little debate within the scientific community that the HCV 
epidemic is largely the result of using unsterilized needles during the PAT campaign 
between the 1960’s and the 1980’s.  Numerous cross-sectional studies have found age to 
be a significant confounder between HCV and history of medical procedures such as 
receiving injections and blood transfusions.3,6,21-22  Prior to the introduction of oral 
schistosomiasis treatments, formal medical procedures explained an overwhelming 
majority of HCV infections.   
 Unfortunately little has been done to characterize HCV dynamics now that 
sterilization and blood screening programs have nearly eliminated that mode of 
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transmission.  Prevalence studies show a significantly lower level of HCV infection 
among younger individuals, with rural rates near 12% and urban rates at a far lower 2-
3%.3-4,15-18  This still exceeds the WHO’s definition of high endemicity (4%), leaving 
Egypt’s position as a leading country in the burden of HCV unchanged.  Recent cross-
sectional studies have found little evidence that formal medical procedures still contribute 
to transmission.  In addition, informal medical procedures, such as circumcision 
performed by a barber, show significant associations but can only explain between 10-
20% of the infections.3-4,6  Some have suggested that intrafamilial transmission may be 
crucial in transmission, but the hypothesis has yet to be specifically tested.23-25  Mohamed 
et al. (2005) found a significant association between incident cases and individuals with 
HCV positive family members, but they did not investigate specific routes for 
intrafamilial transmission.  Though illuminating, such reports bring us no closer to 
inference regarding the future of HCV, and consequently the future of liver disease, in 
Egypt. 
 Incidence estimates.  To address the knowledge gap noted above, we calculated 
past age-specific HCV incidence rates using a method that analyzes HCV prevalence data 
from a one-time cross-sectional survey.  Though originally developed for studying 
chronic diseases like glaucoma, Saidel et al demonstrated the validity of this method 
when compared with observational data from a HIV/AIDS study.12  As was expected, we 
identified very high incidence rates among the population older than 30 years.  In the 
population younger than 30 years, which would be largely comprised of individuals 
unaffected by the PAT campaign, we noted a continuous decline in incidence rates.  
Despite lower incidence rates, they are still between 2 and 3 per 1,000PY among 5-14 
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year olds.  This suggests that transmission is indeed still occurring among the younger 
population despite the elimination of PAT and intense measures to reduce other 
iatrogenic exposures.  It is imperative that we conduct longitudinal studies to gather 
observational data both to validate these findings as well as to test hypotheses regarding 
the current dominating modes of transmission. 
 The authors are aware that the incidence estimates are only as valid as the model 
assumptions are robust.  The model is subject to some limitations, the most important 
being the assumption of constant incidence rates.9-12  The degree to which violation of the 
constancy assumption may have affected model estimates is unpredictable and difficult to 
assess.  We were unable to acquire prevalence data for age intervals less than 5 years.  It 
is possible that the constancy assumption was violated is some of these age groups, but 
based on our knowledge of the natural history of HCV and the strong influence of 
widespread PAT and iatrogenic exposures as the driving force of infection among the 
older age groups, we feel it is not unreasonable to have 5-year age intervals for this 
population.  Since the primary modes of transmission among younger individuals have 
yet to be clearly identified, the probability of violating the constant incidence assumption 
is likely greater, but we believe we have reasonable resolution in examining incidence 
among the younger populations as well. 
 In addition, because HCV is an infectious disease with a high prevalence in 
Egypt, it is possible that the composition of risk groups will change as the population at 
risk becomes saturated with infection. Because the steady-state condition assumed by the 
model is only approximately met, the relation between prevalence, incidence, and 
duration that drives the model will only produce rough estimates.12 
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 The Podgor and Leske-based method can result in negative estimates of the 
incidence rates if prevalence at an older age is sharply less than at an earlier age.9,12 Such 
an estimate is obviously invalid, and indicates either of two things: 1) a lack of power 
and/or too much variability between the age groups in the data used; or 2) the model 
assumptions do not hold in the age range being examined.  For this reason we were 
unable to get incidence estimates for age groups over 50 years when age-specific 
prevalence begins to decline.  This decline among older populations supports the 
hypothesis that the population aged 30-50 years was the most affected by the PAT 
campaign.  It would be valuable to gain prevalence data of the older population in smaller 
age group intervals and in different geographic locations to examine HCV incidence and 
PAT trends more closely. 
 Lastly, although the prevalence of HCV infection in Egypt is relatively high, the 
incidence of new infections needed to maintain prevalence is still low enough that it is 
difficult to obtain precise incidence estimates. Therefore, the model should not be used to 
measure changes in incidence rates over time or differences in incidence rates between 
risk groups. Again, this was largely the reason we chose to estimate incidence from only 
one study.  While it was attractive to consider calculating estimates from multiple studies, 
it would be difficult to tease apart possible violations of assumptions when attempting to 
compare results or draw broader conclusions.  True longitudinal incidence studies are still 
the best way to identify nuances in incidence trends across age, time, and space. 
 Future HCV-related morbidity/mortality in Egypt.  Our natural history model 
predicted 127,821 deaths from decompensated cirrhosis and 117,556 deaths from 
hepatocellular carcinoma due to the HCV epidemic over the next 10 to 20 years.  We also 
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calculated that the infected cohort would spend 750,210 years in the health state of 
decompensated cirrhosis, 132,894 years in the health state of hepatocellular carcinoma, 
and lose 32.86 million years of life in comparison to an age-sex-matched non-infected 
cohort.   
 Our projections may have underestimated total HCV-related morbidity and 
mortality for a few reasons.  We decided to exclude all cases of acute hepatitis.  Egypt 
does not have highly accurate data regarding acute infection and its natural history.  For 
this reason, we chose to limit our natural history model and projections to those with 
chronic HCV infection. 
 In addition, we did not consider the possibility of accelerated progression among 
older cases or those co-infected with HBV or HIV, all of whom may be more likely to 
develop hepatic complications.26  To date there has only been one other model 
constructed to look at HCV specifically in Egypt, and it fitted a model to historic data.27  
Though there was evidence for age and sex influencing parameter estimates, 
confirmatory observational data are presently not available for comparison.  
Consequently, we elected to work with a more conservative model, assuring a baseline, 
or underestimated, projection of future morbidity and mortality.  The same number of 
people were infected with HBV and HCV during the PAT campaign; however, HBV only 
caused chronic infections in approximately 5% of infected individuals, whereas chronic 
HCV infection developed in 70% to 80%.3,6  This can be explained by the natural history 
of HBV, where the probability of developing chronic infection decreases with age.28  
Since most individuals receiving PAT were 10-15 years or older, they were at less risk 
for developing persistent HBV infection.6 
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 Our analysis suggested the health burden related to premature mortality or 
disability from decompensated cirrhosis or hepatocellular carcinoma may be very high.  
Despite the remarkable decline in hepatitis C since the end of the PAT campaign, 
mortality related to existing cases will likely continue to increase over the next 10 to 20 
years, similar to the results of Deuffic-Burban et al (2006).   
 There is an urgent need to address this problem as HCV infection is frequently 
asymptomatic until cirrhosis develops, when treatment is less effective.  More research 
regarding cost-effectiveness of screening for HCV infection and indications for treatment 
is needed to help guide public health policy in this area.  Continued research on the 
natural history of hepatitis C and the development of new treatments should remain top 
priorities not only for Egypt, but for global health as well. 
 Conclusion.  The value of these estimates is that they inform policy makers about 
the rates at which age-specific groups are becoming infected with HCV and what these 
estimates will mean in terms of future morbidity and mortality. This information is 
crucial, because it can lead to conclusions about the level and direction of the HCV 




Table 5.1  Health state transitions and transition probability estimates used in the 
Markov simulation.  Upper and lower bound estimates for sensitivity analysis were 
determined based on error associated with parameter estimates found in the literature. 
 
Health State (i) Health State (i+1) Annual Probability Lower Bound 
Upper 
Bound 
HCV Infection Chronic Infection Infection Resolution 
0.75 





0.05/20 (<40 years) 














Death from D Cirrhosis 
Background Mortality** 0.186 0.137 0.300 
Hepatocellular 
Carcinoma Death from HCC*** 0.95   
 
* The compensated cirrhosis transition probability is 0.05 over 20 years if the individual 
was initially infected with HCV prior to 40 years of age. The transition probability is 0.2 
over 20 years if the individual was aged 40 years or older at the time of initial HCV 
infection [Appendix 5.1]. 
** Background mortality is defined by age-sex-specific rates obtained from WHO [14]. 
*** All death from hepatocellular carcinoma is assumed to be attributed to it. 
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Table 5.2.  Data sources for calculating summary age-specific prevalence of HCV 
infection used in both the incidence estimates and Markov models. 
 
Author Year Region of Egypt N 
Mohamed, et al15 







Arafa, et al17 2002 Upper 2261 
Medhat, et al18 2002 Lower 6033 







Table 5.3.  Indirectly estimated age-specific incidence rates for HCV in Lower Egypt 
using smoothed age-specific prevalence measures.  Data were fit to a logistic curve:  








Incidence (SE)  Mean Annual 
Incidence per 
1,000PY 
5-9 1.0 2.2 0.010 (0.01) 2.01 
10-14 3.0 3.2 0.014 (0.01) 2.89 
15-19 5.0 4.6 0.021 (0.01) 4.13 
20-24 7.5 6.5 0.029 (0.01) 5.85 
25-29 7.5 9.3 0.041 (0.03) 8.19 
30-34 12.5 13.0 0.056 (0.03) 11.28 
35-39 22.0 17.9 0.076 (0.04) 15.21 
40-44 33.0 24.1 0.010 (0.05) 19.99 
45-49 35.5 31.7 0.127 (0.06) 25.47 
50-54 40.5 40.4 ------------------ --------- 
55-59* 32.0 49.8 ------------------ ---------
60+* 22.5 59.1 ------------------ ---------
 




Table 5.4.  Predicted HCV-related morbidity and mortality, measured as life years or 
number of deaths.  Upper and Lower bound estimates were obtained by varying 
parameter estimates in accordance with their margin of error as indicated by the 
literature. 
 
Health State Estimate Lower Bound Upper Bound 
Compensated Cirrhosis (Life Years) 3,862,643 2,902,917 3,881,476
Decompensated Cirrhosis (Life Years) 750,210 392,042 818,895
Hepatocellular Carcinoma (Life Years) 132,894 68,132 176,333
Decompensated Cirrhosis (Mortality) 127,821 48,728 227,701












Figure 5.2.  Raw age-specific HCV prevalence proportion in Lower Egypt, 2002 (Data 
from Arafa et al, 2005) plotted with smoothed age-specific prevalence estimates.17  































Figure 5.3.  Predicted mortality due to HCV-related decompensated cirrhosis and 
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SUMMARY OF MAJOR FINDINGS AND RESEARCH IMPLICATIONS 
This study presents various findings that are similar to, but also different from, 
those that have previously addressed HCC in the Middle Eastern region.  As has been 
shown consistently in other studies, male incidence was considerably greater than that for 
females.  Additionally, the incidence rate of HCC in Gharbiah was 3.5 times higher than 
that reported in the United States.  Such results were seen in the overall age-adjusted 
incidence rates, as well as the age-specific rates in age groups older than 40 years, among 
both males and females.  This finding expands upon reports in the United States NCI and 
MECC publications for a shorter period, 1999-2001.1  Our similar findings for a longer 
period suggest that variation in rates truly reflect different risk factor profiles of these two 
populations, warranting further prospective studies. 
 The most notable finding of this study, however, was the statistically significant 
geographic variation in incidence of HCC among districts within Gharbiah province.  
Incidence ranged from 12.9/100,000PY (Kotour) to less than half that rate at 
6.1/100,000PY (Samanoud).  Districts were similar with respect to age distribution and 
sex-ratios, suggesting that the at-risk populations were fairly homogeneous.  
Consequently, this observed heterogeneity is likely attributable to variation in local risk 
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factors that future studies may investigate.  One feature that was consistent across 
districts was that HCC incidence among urban individuals was nearly twice that of rural 
residents, in contrast with reports that HCV prevalence is higher among rural residents.   
Significant variation in incidence at the district-level provided the motivation for 
more formal spatial analyses to test the hypothesis that HCC spatially clusters in 
Gharbiah Province.  We applied two cluster detection methods that generate test statistics 
through independent means.  Both methods detected significant high- and low-risk 
clusters that were spatially similar, suggesting our results are robust.  When combined 
with the fact that this population is quite stable and relatively homogeneous in terms of 
confounders, our findings suggest an underlying clustering of primary HCC risk factors.  
In the absence of detailed natural history or incidence studies, we used sero-
prevalence and cross-sectional data to help guide our inference.  Reports concerning 
HBV have suggested a relatively homogeneous geographic distribution of infection, with 
overall declining rates due to the successful implementation of the HBV vaccine.2-3  
Studies examining HCV have shown higher levels of infection among residents in Lower 
Egypt versus those in Upper Egypt.1,4  Higher levels of HCV have also been observed in 
rural regions as opposed to urban areas.1,4  Several studies have suggested that HCC is 
increasingly associated with HCV, and this trend is expected to continue as HBV rates 
decline. 1, 4-5 
Aside from understanding viral dynamics, there is also increasing interest in the 
role environmental contaminants may play in the development of HCC in Egypt.  To 
address this concern in an exploratory way, we examined the relationship between 
village-level HCC incidence and distance to factories and drainage canals.  Factories can 
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produce a great deal of contaminants that may be present in the air and water of the 
surrounding regions.  It is also likely that employees of the factories reside in nearby 
villages.  Drainage canals are another potentially point source for environmental 
contaminants.  These waterways receive the vast majority of water-related factory waste 
as well as any agricultural runoff (pesticides, etc).  We were unable to find any 
association between incidence and distance to possible environmental point sources.  This 
does not necessarily reject the significance of such factors, but it may suggest that their 
underlying contribution to HCC burden is obscured by more dominant factors, i.e. HBV 
and HCV.  
Since information regarding schistosomiasis and/or HCV infection were 
unavailable for the HCC cases included in this study, we opted to examine the PAT 
hypothesis from a new angle.  We hypothesized that if such a strong link existed between 
schistosomiasis and HCC (via PAT), it should be reflected in the examination of the one 
type of cancer most associated with schistosomiasis of the urinary bladder: squamous cell 
carcinoma. 
 Upon repeating our methods for the cluster analysis of HCC for squamous cell 
carcinoma, we again found significant high- and low-risk regions with strong agreement 
across the two methods.  In addition we found strong overlap in the primary high-risk 
cluster for both cancers as well as for all low-risk clusters except one for squamous cell 
carcinoma.  Our test for correlation between spatial clusters of HCC and SCC-B found a 
strong association among low clusters and a marginal association among high clusters.  
Though we do not suggest that all spatial variation in HCC can be explained by 
squamous cell carcinoma, the overlap present among the majority of clusters, which was 
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identified by two separate cluster detection methods, seems hardly a coincidence.  Of 
particular importance is the fact that this cohort of cases represents a population still 
burdened by schistosomiasis as well as the early wave of individuals affected by the PAT 
campaign.  We believe our findings support the strong connection between 
schistosomiasis and HCC, but more research is necessary to determine if the association 
is due to chronic schistosomiasis infection or exposure to PAT treatment. 
Motivated by the absence of viral data for the HCC cases as well as the general 
lack of natural history or incidence studies characterizing the dynamics of HBV and HCV 
in Egypt, we conducted a systematic review and meta-analysis of HBV and HCV sero-
prevalence.  Our analysis confirmed reports of geographic heterogeneity in HCV 
prevalence among the apparently healthy population.1,4  We found prevalence to be 
significantly higher in Lower Egypt as opposed to Upper Egypt, which in turn supports 
the hypothesis of PAT as the dominant force driving the HCV epidemic.  Individuals 
living in Lower Egypt experienced a greater burden of schistosomiasis, and therefore a 
greater level exposure to PAT.1,4  This is in contrast to what we saw with HBV, which 
appeared to be higher in Upper Egypt versus Lower Egypt.   
We were also able to examine the relationship of HCV with urban and rural 
populations, something we had been unable to probe in our earlier GPCR studies.  
Findings were consistent with the hypothesis that HCV prevalence is higher among rural 
residents than urban residents.6-7  This is also in line with the PAT hypothesis; that rural 
residents would have a greater burden of schistosomiasis, and therefore greater exposure 
to PAT.6-7  It is in contrast, however, with our earlier results showing greater risk for 
HCC among urban residents.  Due to the significant lag time between viral infection and 
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development of HCC, it is possible Egypt is witnessing the end of a cohort of higher 
urban exposure that will soon transition to a population dominated by rural exposure.  
Unfortunately, we were unable to find this type of disaggregated data for HBV for 
comparison. 
For both viruses among healthy population-based samples, we found adults had a 
significantly higher prevalence than children, supporting a cohort effect.  For HBV, it 
seems likely that the cohort effect would be related to the introduction of the hepatitis B 
vaccine in 1992, which was incorporated into the Expanded Programme on 
Immunisation, and is only given to children, leaving adults at the time of program 
implementation unvaccinated.  The cohort effect seen in HCV is likely related to the 
early association between the parenteral antischistosomiasis therapy (PAT) campaign and 
HCV transmission.  Since several of the childhood HCV studies were late enough that 
none of the children would have been exposed to the PAT campaign, it does appear that 
HCV has continued to be transmitted.   
In addition to age differences, we examined time (year) trends in HBV and HCV 
prevalence.  As was expected to some degree, HBV prevalence was relatively low 
overall, but has experienced a slight decrease over the time period included here, 
probably due to the implementation of earlier control measures followed by the vaccine.  
Infection levels in children suggest that this infection may soon be an insignificant 
element of liver disease in Egypt.  Prevalence of HCV, however, showed greater variance 
over time.  Among both children and adults there was a general decline in prevalence 
over time, with adults stabilizing at just below 15%, and children continuing to drop to 
nearly 1% by the period 2000-2004.  Regression analyses found significant time 
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interactions for both HBV and HCV, suggesting a more complicated shift in prevalence 
patterns over time that includes geographic changes as well.   
Among HCC cases, we found the overall prevalence of HBV among HCC cases 
to be nearly 25%, and the prevalence of HCV infection to be as high as 84%.  We also 
noted some differences within infections over time, though they were not statistically 
significant, possibly a result of low power.  It appeared that HBV infection declined from 
a prevalence of 30% between 1991-1996 to 22% between 1997-2004.  Conversely, HCV 
infection among HCC cases may have increased slightly over this same time period from 
80 to 86%.  This seems fitting when we consider the impact of different cohort effects.  
Current cancer cases represent individuals being exposed to these viruses 20-30 years 
prior.  These cases may represent the individuals at the end of the pre-HBV vaccine 
period and the beginning of the PAT campaign.  Based on general population estimates, it 
seems likely that prevalence of HBV will continue to decline and HCV will continue to 
increase among HCC cases, at least for a while.  This has been supported by a projections 
from a mathematical model designed to predict the burden of HCV in Egypt over the next 
couple of decades.7  What will happen after that will depend largely on the new HCV 
incidence patterns in the absence of the PAT campaign, which remain to be quantified by 
future research. 
 Based on the results of our meta-analysis, we pursued mathematical techniques to 
indirectly calculate past HCV incidence to further probe the epidemic and PAT cohort 
hypothesis.  As was expected, we identified very high incidence rates among the 
population older than 30 years.  In the population younger than 30 years, which would be 
largely comprised of individuals unaffected by the PAT campaign, we noted a continuous 
 
 155
decline in incidence rates.  Despite lower incidence rates, they are still between 2 and 3 
per 1,000PY among 5-14 year olds.  This suggests that transmission is indeed still 
occurring among the younger population despite the elimination of PAT and intense 
measures to reduce other iatrogenic exposures. 
 In addition to reconstructing previous incidence rates and identifying a cohort of 
exceptionally high sero-prevalence, we constructed a Markov model to predict the burden 
of HCV-related liver disease in Egypt over the next 10 to 20 years, which would largely 
quantify the outcome of this special cohort.  Our natural history model predicted 127,821 
deaths from decompensated cirrhosis and 117,556 deaths from hepatocellular carcinoma 
due to the HCV epidemic over the next 10 to 20 years.  We also calculated that the 
infected cohort would spend 750,210 years in the health state of decompensated cirrhosis, 
132,894 years in the health state of hepatocellular carcinoma, and lose 32.86 million 
years of life in comparison to an age-sex-matched non-infected cohort. 
Data considerations.  Our HCC studies from Gharbiah are unique in comparison 
to other hospital- and clinic-based reports that have previously been published for HCC 
in Egypt, as our analyses were based on HCC and squamous cell carcinoma of the 
bladder cases from a population-based cancer registry and appear to be largely complete 
and highly representative.  The GPCR is scientifically and financially supported by the 
United States National Cancer Institute, and it has quality assurance from US-SEER and 
the International Association of Cancer Registries.  Standard procedures for training 
registrars and for data collection, processing, and transmission enhanced the accuracy of 
data.  In addition, the population-based structure improves our ability to draw conclusions 
about the entire province from the study results. 
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Our results represent a high degree of internal and external validity.  Data on the 
vast majority of cases included complete demographic and geographic information.  
There was little evidence of interannual variation in case reporting for either cancer for 
our study period, which was particularly reassuring.  In addition, external review of the 
data collected by the GPCR has found its coverage to exceed 90%, improving our 
confidence in accurate numerator estimates.8  Though it is possible the number of cases 
could be underestimated due to misclassification, there is no reason to believe that this 
underestimation is biased in any significant way.  Access to healthcare is similar across 
the province, and there is nothing to suggest that physicians diagnose differently in any 
systematic way.  Therefore, we consider the case data that we analyzed to be valid for the 
populations at risk, and the results to be generalizable at least to the people of Gharbiah 
Province. 
Denominator estimates were based on census reports from 1996 and published 
census projections for 2001 and 2005.  We believe it was reasonable to calculate 
population estimates using linear interpolation, as this is a fairly stable population, 
experiencing the majority of its change through birth and death rates (low population 
mobility).  Data were available at the village level and age- and sex-specific values were 
provided.  We were unable to detect any significant differences between villages and the 
Province in aggregate with respect to age and sex distributions, suggesting that villages 
could be compared without serious concern for compromising our conclusions due to 
these important confounding variables.  We are confident that this increases the accuracy 
of our calculations, since both numerator and denominator data were available at the 
same high level of resolution. 
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 Spatial data were based on maps published by the Egyptian General Survey 
Authority, which followed international guidelines in the creation of their maps.  A brief 
comparison of calculated point coordinates with those obtained from a handheld GPS unit 
for the same location suggested the maps were internally consistent and geographically 
accurate. 
Much of the work for Chapters IV and V was based on a systematic review of the 
literature.  It is possible that despite our extensive literature search, the specific search 
terms used may not have captured all quality papers published in peer-reviewed indexed 
journals. To counter this problem, we supplemented our electronic search by a hand 
search of references from selected articles, but there is always the possibility that we 
missed some data.  
We attempted to gain representative samples of the Egyptian healthy population 
by accepting community-based samples, but we also included some large scale 
convenience samples such as healthy pregnant women attending clinics and voluntary 
blood donors.  John, et al have questioned the inclusion of voluntary blood donors in 
systematic reviews, suggesting data from replacement donors would be less biased.9 
Batham, et al. conducted an analysis of HBV studies in Delhi that used voluntary donors, 
replacement donors and ante-natal mothers.10  Analyses revealed that all populations had 
prevalences close to the overall mean, suggesting it was appropriate that all these groups 
be included in systematic reviews.  
The extent to which the HCC cases we reported upon are representative is also 
unclear, since in most cases only hospital-based studies were available.  We did focus on 
cancer studies from the larger, nationally recognized cancer centers, which serve as 
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diagnostic and treatment facilities for the overwhelming majority of cancer cases 
throughout Egypt. 
 In addition to the data sources used in the systematic review and calculations, it is 
important to consider the restrictions on inference associated with the modeling methods 
we selected.  The incidence method used in Chapter V is subject to some limitations, the 
most important being the assumption of constant incidence rates.11-14  It is possible that 
the constancy assumption was violated is some of these age groups, but based on our 
knowledge of the natural history of HCV and the strong influence of widespread PAT 
and iatrogenic exposures as the driving force of infection among the older age groups, we 
feel it is not unreasonable to have 5-year age intervals for this population.  Since the 
primary modes of transmission among younger individuals have yet to be clearly 
identified, the probability of violating the constant incidence assumption is likely greater, 
but we believe we have reasonable resolution in examining incidence among the younger 
populations as well. 
 In addition, because HCV is an infectious disease with a high prevalence in 
Egypt, it is possible that the composition of risk groups will change as the population at 
risk becomes saturated with infection. Because the steady-state condition assumed by the 
model is only approximately met, the relation between prevalence, incidence, and 
duration that drives the model will only produce rough estimates.14 
 The Podgor and Leske-based method can result in negative estimates of the 
incidence rates if prevalence at an older age is sharply less than at an earlier age.11,14 Such 
an estimate is obviously invalid, and indicates either of two things: 1) a lack of power 
and/or too much variability between the age groups in the data used; or 2) the model 
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assumptions do not hold in the age range being examined.  For this reason we were 
unable to get incidence estimates for age groups over 50 years when age-specific 
prevalence begins to decline.   
 Lastly, although the prevalence of HCV infection in Egypt is relatively high, the 
incidence of new infections needed to maintain prevalence is still low enough that it is 
difficult to obtain precise incidence estimates. Therefore, the model should not be used to 
measure changes in incidence rates over time or differences in incidence rates between 
risk groups.  Again, this was largely the reason we chose to estimate incidence from only 
one study.  While it was attractive to consider calculating estimates from multiple studies, 
it would be difficult to tease apart possible violations of assumptions when attempting to 
compare results or draw broader conclusions.  True longitudinal incidence studies are still 
the best way to identify nuances in incidence trends across age, time, and space. 
 Our Markov model projections of future burdens may have underestimated total 
HCV-related morbidity and mortality.  We excluded all cases of acute hepatitis.  Egypt 
does not have highly accurate data regarding acute infection and its natural history.  For 
this reason, we chose to limit our natural history model and projections to those with 
chronic HCV infection. 
 In addition, we did not consider the possibility of accelerated progression among 
older cases or those co-infected with HBV or HIV, all of whom may be more likely to 
develop hepatic complications.15  To date there has only been one other model 
constructed to look at HCV specifically in Egypt, which fitted parameters to historic 
data.7  Though there was evidence for age and sex influencing parameter estimates, 
confirmatory observational data are presently not available for comparison.  
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Consequently, we elected to work with a more conservative model, assuring a baseline, 
or underestimated, projection of future morbidity and mortality. 
 
SUGGESTIONS FOR FUTURE RESEARCH 
 Cancer Studies.  As in many developing countries, Egypt is undergoing an 
epidemiologic transition.  With increasing urbanization, smoking rates, environmental 
exposures, and aging, in addition to the maturing HCV epidemic, it is likely that HCC 
will continue to rise for the next few decades. Therefore, further studies to assess the 
magnitude and risk factors of HCC in Egypt and other developing countries seem 
warranted.  Our research produced important preliminary insights that can be used to 
develop more refined, prospective analyses of HCC risk in Egypt.  Since chronic HCV 
does not typically lead to carcinogenesis for 10-30 years following infection, the rates of 
liver cancer can be expected to continue increasing until the cohort of PAT-related 
infected individuals has worked its way through.1,6 
 Our research suggested that spatial patterns of HCC did not seem to be influenced 
by environmental point sources of pollutants, but may be linked to the spatial distribution 
of squamous cell carcinoma of the bladder.  Our use of high quality population-based 
data in addition to rigorous statistical methods suggests our findings are highly robust.  
Future studies should focus on the dynamics of HCC risk factors in order to better predict 
regions at greater risk for disease.  These initial spatial findings have already stimulated 
ongoing collaborations to begin developing studies that would include case enrollment 
and detailed risk factor data collection to improve inference regarding the relative 
significance of different risk factors in Egypt.  We hope these analyses will help untangle 
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the complex etiology of HCC and assist policy makers in generating more efficient 
prevention and control programs. 
Viral Dynamics.  It is understood that only a large, national epidemiological 
study can provide a definitive answer regarding the overall situation of hepatitis B and C 
viruses in Egypt.  Incidence data are essential to clarify the future of the HCV epidemic 
in Egypt.  The PAT crisis has ended; no new infections are being generated through that 
route.  It is imperative that we determine present modes and rates of transmission to 
refine prevention efforts.  Detailed risk factor data are needed to further characterize the 
shapes of the HBV and HCV infection curves and distinguish between the effects of 
population migration, changing risk factor patterns, etc.  It would also be valuable to 
match prevalence figures with incidence studies to reconstruct the different epidemic 
curves, shedding light on viral dynamics and guiding predictions about future trends in 
infection.  
There is an urgent need to address this problem as HCV infection is frequently 
asymptomatic until cirrhosis develops, when treatment is less effective.  More research 
regarding cost-effectiveness of screening for HCV infection and indications for treatment 
is needed to help guide public health policy in this area.  Continued research on the 
natural history of hepatitis C and the development of new treatments should remain top 
priorities not only for Egypt, but for global health as well. 
 
CONCLUSIONS 
 Our findings highlight the significance of continuing prevention of HBV through 
vaccination campaigns as well as the development of an integrated strategy for the 
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prevention of HCV infection that should include screening of blood donations, safe 
injection practices, and avoidance of unnecessary injections.  The value of results from 
mathematical techniques such as those presented here is that they begin to inform policy 
makers about the rates at which age-specific groups are becoming infected with HCV and 
what these estimates will mean in terms of future morbidity and mortality until the 
observational data are available to further refine estimates and predictions.  
Ongoing collaborations are building upon these preliminary findings to develop 
studies that will examine HCC cases from the point of intake and acquire HBV/HCV test 
results to expand our inference regarding the relative importance of certain risk factors on 
HCC in Egypt.  We have also embarked upon discussions of incidence and natural 
history studies focused on HCV.  This information is crucial, because it can provide clues 
about the level and direction of the HCV epidemic in Egypt that might be less readily 
apparent from the prevalence data alone.  Such analyses should help define the complex 
etiology of liver disease in Egypt, enabling policy makers to create targeted, more 
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